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Abstract of Dissertation

Reciprocal Regulation of Par‐4 and Caspase‐8 in the TRAIL signaling pathway

Par‐4 is a pro‐apoptotic tumor suppressor that is mutated, suppressed or inactivated in
cancer. Par‐4 exploits components of the extrinsic pathway to cause apoptosis
selectively of cancer cells. This study identified Par‐4 as an essential component of the
apoptotic pathway induced by TRAIL, which selectively targets cancer cells. RNA
interference‐mediated knockdown of Par‐4 rendered cancer cells unresponsive to
TRAIL‐induced apoptosis. Cells with knocked‐down levels of Par‐4 were deficient in the
activation of the apoptosis‐initiator caspase‐8 and the apoptosis‐effector caspase‐3 in
response to TRAIL. Par‐4 was identified as a critical mediator of membrane
translocation of caspase‐8 and the adapter protein FADD. Surprisingly, Par‐4 was also
found to interact with caspase 8 in untreated cells, and was cleaved at the N‐terminus at
aspartic acid residue 123 in response to TRAIL. This, along with another cleavage by
caspase‐9 effectively generated a fragment containing the functional module of Par‐4,
the SAC domain, which is sufficient for apoptosis of cancer cells. Moreover, TRAIL
activated caspase‐8 was also found to be involved in nuclear translocation of Par‐4, a
crucial step during apoptosis induction by Par‐4. Together, our findings suggest that Par‐
4 is an essential downstream target of caspase‐8 that is activated by TRAIL signaling and
that, in turn, activates caspase‐8 and the downstream apoptotic pathway in response to
TRAIL.
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Chapter One

Introduction
Apoptosis or programmed cell death is a physiologically essential, conserved,
energy dependent phenomenon necessary for proper maintenance of homeostasis in all
metazoans. Cell death is indispensable for processes such as organogenesis, cell lineage
differentiation, disposal of infected, damaged, aged or non‐functional cells, and immune
function, to name a few. Among the different forms of cell death, apoptosis is a very
complicated process that has evolved to maintain order. Another commonly observed
mode of death is necrosis that occurs as a result of trauma where cell swelling, bursting
and leakage of contents into the surrounding tissue leads to inflammation. Apoptosis, in
contrast, does not incite tissue injury or an inflammatory response, and can be caused
by both physiological and pathological signals.

Apoptosis – the process
A cell undergoing apoptosis bears certain defining morphological features, such
as shrinkage of the cytoplasm and nucleus, membrane blebbing, preservation of
organelle structure, and containment of cell contents within membrane bound
apoptotic bodies. In particular, chromatin condensation due to oligonucleosomal DNA
fragmentation, which results in margination of chromatin along the nuclear membrane,
and ‘Apoptotic DNA laddering’, is considered a hallmark of apoptosis, although recent
studies indicate not all cells exhibit such an internucleosomal degradation pattern
(Zakeri et al., 1993). Moreover, phosphatidylserine, a phospholipid that is normally
present on the inner leaflet of the plasma membrane, is flipped over and exposed on
the surface of apoptotic cells thus leading to recognition by the macrophages and
prompt tissue clearance. Underlying such visible alterations is the activation of a series
of enzymes, the caspases (Cysteine dependent ASPartic acid specific proteASE), which
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are synthesized as inactive zymogens that lie dormant until awakened by apoptotic
signals.

A cell is programmed to destroy itself when conditions of abnormality are
sensed, either internally or in the extra‐cellular environment. The cell has, as part of its
apoptotic machinery, a variety of sensors. For example, cell surface receptors, such as
EGFR (Epidermal Growth Factor Receptor), IGFR (Insulin like Growth Factor Receptor),
certain GPCR (G‐Protein Coupled Receptor), Integrins and other cell attachment
molecules that signal for survival upon perception of surroundings conducive to growth,
while death receptors, such as Fas, TNFR (Tumor Necrosis Factor Receptor) and
DR4/DR5 (Death Receptor4 or Death receptor 5), trigger apoptosis upon recognition by
their cognate ligands. Intracellular sentries initiate apoptosis in response to insults, such
as DNA damage, hypoxia, energy deficiency, ionic imbalance and oncogene activation
(Hanahan and Weinberg, 2000).

Among the intracellular triggers, when the primary elements of cell
transformation, namely, oncogene activation and DNA damage, fail to activate
apoptosis due to inactivation or defects in the apoptotic pathway, a significant road
block to tumorigenesis is overcome. Typically, the receipt of pro‐transforming signals in
normal cells triggers one of the two pathways of apoptosis: the extrinsic or intrinsic
pathway. Along the extrinsic pathway, binding of the cytokines FasL, TNF‐α (Tumor
Necrosis Factor), or TRAIL (TNF Related Apoptosis Inducing Ligand) to their respective
oligomerized receptors at the cell surface allows formation of a DISC (Death Inducing
Signaling Complex). DISC consists chiefly of the receptor, an adaptor protein FADD (Fas
Associated Death Domain) and pro‐caspase‐8, where caspase‐8 is activated. The
activated caspase‐8 then directly cleaves and activates the effector caspases, caspase‐3,
‐6, and ‐7, which are responsible for dismantling the cell and also generating the
classical morphological changes observed during apoptosis (Figure 1.1).
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Figure 1.1 : Extrinsic and Intrinsic pathways of Apoptosis

FasL, TNFα, TRAIL
Fas, TNFR, DR4/5

Growth Factor
deprivation, DNA
Damage, Oxidative
stress

FADD
Pro‐caspase‐8/10
Bid

Bax,Bak
Bcl‐2,Bcl‐xl

Caspase‐8

Cytochrome‐c

Apoptosome

Caspases ‐3,6,7

Caspase‐9

Apoptosis

3

Figure 1: Extrinsic and Intrinsic pathways of cell death:

Death receptors such as Fas, TNFα and TRAIL initiate the extrinsic pathway of cell death
when engaged by their respective ligands. Caspase‐8 is activated by death receptor
signaling with the aid of adapter protein FADD. The activated caspase‐8 then activates
caspase‐3. In the cell intrinsic pathway, stress signals such as growth factor deprivation
and DNA damage induce release of cytochrome‐c from the mitochondria via pro‐
apoptotic proteins Bax and Bak. Additionally, cytochrome‐c is also released by the action
of caspase‐8 substrate Bid, which activates Bax and Bak. This process is inhibited by the
anti‐apoptotic Bcl‐2 family proteins. Cytochrome‐c release from the mitochondria leads
to activation of caspase‐9 in the apoptosome complex. is Caspase‐3 is activated
downstream of caspase‐9 and results in apoptosis.
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The mitochondria and the Bcl‐2 family of proteins play a major role in the
intrinsic pathway. The pro‐apoptotic Bcl‐2 family members, Bax and Bak, allow the
release of cytochrome c from the mitochondria, which is inhibited by the anti‐apoptotic
Bcl‐2 proteins such as Bcl‐2, Bcl‐xL, Mcl‐1, and Bcl‐W, and the balance between these
two groups determines the fate of the cell. The cytochrome c that is released from the
mitochondria enters into complex with an adaptor protein APAF‐1 (Apoptotic Protease
Activating Factor‐1), pro‐caspase‐9 and ATP to activate caspase‐9, which then activates
the effector caspases (Figure 1.1) (Danial and Korsmeyer, 2004).

Apoptosis is exceedingly integral to the maintenance of proper health that,
disorders in the regulation of apoptosis manifest as those of excess cell death such as
chronic or acute degenerative diseases, immunodeficiency and infertility, or those of
insufficient death such as cancer and autoimmunity (Danial and Korsmeyer, 2004).

Apoptosis in cancer
A cell becomes cancerous, or is transformed, when it taps into its potential for
uncontrolled cell division. Such unrestricted division can result from the cell responding
to promiscuous signals for proliferation, in addition to evading intrinsic defenses of
growth arrest and apoptosis.

Appreciation of the contribution of apoptosis to transformation inhibition came
with the recognition of Bcl‐2 as the oncogene in B‐cell follicular lymphomas (Danial and
Korsmeyer, 2004). Bcl‐2 is over‐expressed in a wide variety of cancers, such as gastric,
colorectal, renal, neuroblastomas, non‐Hodgkin’s lymphoma, acute and chronic
leukemias, prostate, breast and lung, and this dysregulation is associated with disease
progression and development of chemo resistance (Reed, 1995). Likewise, the pro‐
apoptotic member of the Bcl‐2 family, Bax, is inactivated by mutation in cancers of
colon, stomach and hematopoietic origin (Reed, 1999). Among the components of the
extrinsic pathway, FLIP (FLICE Like Inhibitory Protein), an inactive homolog and inhibitor
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of caspase‐8, is over‐expressed in a broad range of tumors, thus inhibiting active
apoptosis during transformation (Djerbi et al., 1999) and providing cancer cells with yet
another strong mechanism of resistance to therapy (Longley et al., 2006; Zhang et al.,
2004). Furthermore, inactivation of the components of the extrinsic pathway offers the
cancer cells a means to escape tumor immune surveillance by the cytotoxic T cells,
which activate death receptors on these recipient cells.

Oncogene activation in a cell generates both proliferative and growth inhibitory
signals in tandem. Growth inhibitory responses of arrest or apoptosis are overpowered
by cytokine signaling and active suppression of cell death, which then leads to
unrestrained proliferation and transformation of cells. Cells undergoing transformation
encounter several cell cycle checkpoints and may experience a transient growth arrest;
nevertheless, in most cases irreparable damage ultimately leads to cell death. Hence,
apoptosis plays a critical role in inhibiting tumorigenesis. Unwarranted activation of
both viral and cellular oncogenes stimulates an apoptotic response. For instance,
papilloma virus oncoprotein E7 and adenoviral oncoprotein E1A are known to trigger
the cell death program and therefore the viruses carry ancillary tools, such as E6 and
E1B proteins, respectively, to quench the apoptotic reaction (Rao et al., 1992;
Tommasino and Crawford, 1995).

Similarly, deregulated expression of cellular

oncogenes, such as c‐myc and Ras, induces apoptosis instead of proliferation when
coupled with growth factor deficiency (Downward, 1998; Harrington et al., 1994). In
addition, inappropriate activation of components of the proliferative pathways such as
the E2F transcription factors, also leads the cell towards suicide (Phillips et al., 1997).

The delicate balance between oncogenes and tumor suppressors in a cell
translates into an intricate equation of tumorigenesis. Not surprisingly, as with most
oncogene activation episodes, loss of a tumor suppressor leads to apoptosis as well, by
the compensatory activation of another; this is exemplified by the inactivation of Rb
(Retinoblastoma protein), which results in induction of p53 dependent apoptosis
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(Morgenbesser et al., 1994). Several tumor suppressor gene products such as p53,
PTEN, APC, NF1, WT1, and BRCA1/BRCA2, function by inducing apoptosis; thus, the loss
of these proteins’ function results in accelerated tumor development, and the cells
exhibit a cell death resistant phenotype in most cases (Davies et al., 1999; Englert et al.,
1995; Morin et al., 1996; Rao et al., 1996). A cell responds to numerous anomalies by
initiating apoptosis that, the concerted loss of tumor suppressors and activation of
oncogenes does not guarantee tumor development, unless defects in the cell death
program are acquired. Moreover, developing deficiencies in the apoptotic pathways is
critical for tumor progression and metastasis as cells must survive in the absence of
anchorage and survival signals from the extracellular matrix.

Role of apoptosis in chemotherapy and therapeutic resistance
Transforming events are many, and each one can be countered individually to
inhibit the process of transformation. Although strategies that negate transforming
events may be therapeutically successful initially, tumor regression and complete
therapy can be easily and efficiently achieved only if all of the cells are able to reinstate
a functional apoptotic response. Consequently, most therapeutic options available
currently utilize extrinsic stress signals to activate the cell death program in the cell.
Cancer cells that retain certain functional components of the apoptotic machinery
undergo spontaneous cell death and this is properly enhanced by therapeutic
interventions in the form of irradiation, cytotoxic chemotherapy, hormone ablation,
cytokine signaling and immunomodulation (Kerr et al., 1994).

One of the most important problems faced during cancer treatment is the
development of multidrug resistant tumors, especially in patients with a previous
treatment history. Although such resistance can be attributed to the upregulation of
Mdr1, a plasma membrane transporter that actively transports drugs to the outside of
the cell, it is seen in only a minority of the cases (Gottesman and Pastan, 1993). Besides,
several cancers acquire resistance to radiation therapy, where transporters have no role
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to play, which together indicate that a process common to a variety of stressors is
responsible. Despite a widespread belief that therapies, being highly toxic, induce cell
death by necrosis, the mechanism of cell death was found to be apoptosis (Lowe et al.,
1993). As with tumorigenesis, defective regulation of apoptosis is a straightforward way
to ensure cell survival following cancer therapy, as various toxic and stress signals
converge on one single pathway to effect cell death. Not surprisingly, loss of p53 (Lowe
et al., 1994) and over expression of Bcl‐2 or Bcl‐xL increase tumor resistance to
antineoplastic agents, such as anthracyclines, topoisomerase inhibitors, DNA
crosslinking agents, and mitotic spindle inhibitors (Fisher et al., 1993; Minn et al., 1995;
Miyashita and Reed, 1992). While most of these treatment strategies highlight the
requirement of an intact apoptotic response, the surrounding normal tissue offers
abundant targets for highly toxic treatments. Hence, the issue of bystander toxicity has
to be addressed in addition, while designing therapies.

Described here, in brief, are certain proteins that play very important roles in
apoptosis, especially of cancer cells; this dissertation is devoted to the study of the
interplay of these proteins under a few experimental conditions modeling certain
physiological and pathological cellular states.

Par‐4 (Prostate Apoptosis Response – 4)
Identification and characterization of Par‐4
Prostate cancer, one of the most common forms of cancer in the United States,
is usually treated by androgen‐ablation, which results in tumor regression by apoptosis.
The prostate tumor consists of a mixed population of androgen‐dependent and ‐
independent cells.

Androgen withdrawal results in the initiation of an apoptotic

response in the androgen‐dependent cells, which rely on a steady supply of hormones
for their survival.
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In the androgen‐dependent cells, the cell‐death program is triggered by the
induction of gene expression in response to intracellular calcium elevation on androgen
withdrawal; this response is bypassed in the androgen‐independent cells and thereby
results in the survival of this population. Accordingly, this therapeutic approach, in
some cases, generates an aggressive relapse because the few androgen‐independent
cells, which did not undergo apoptosis, are essentially selected for survival.

The

androgen‐independent cells can be forced to undergo apoptosis in cell culture
paradigms when intracellular calcium levels are increased with the treatment of the
calcium ionophore, ionomycin. This apoptotic program can be abolished if transcription
or translation inhibitors, such as actinomycin or cyclohexamide, are used, indicating that
gene induction is necessary.

Par‐4 was first cloned by inducing the rat androgen‐independent prostate cells,
AT‐3, with ionomycin to undergo apoptosis.

Using the differential hybridization

strategy, Par‐4 was identified as a member of a new set of genes that are transcribed in
response to calcium elevation. Similarly, Par‐4 expression has been observed during the
involution of rat ventral prostate by apoptosis following castration, and this Par‐4
induction was duly inhibited on pretreatment with the calcium‐channel blocker,
nifedepine (Sells et al., 1994). Par‐4 expression was also inhibited by testosterone in the
ventral prostate. Neither induction nor repression of Par‐4 was observed in the liver,
kidneys, or other organs that bear androgen receptors yet do not undergo apoptosis in
response to castration. In addition, in the initial studies, Par‐4 was induced in cell
culture models exclusively by apoptotic signaling and not during necrosis, growth arrest,
or serum stimulation.

Par‐4 is evolutionarily conserved in vertebrates and is ubiquitously expressed in
tissues of ectodermal, mesodermal, and endodermal origin. Par‐4, however, is absent
from specific cell types (such as lymphocytes, certain smooth muscle cells, the
differentiated ductal cells of the prostate, the epithelial cells of the mammary gland,
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and the terminally differentiated cells of the retina), thus indicating that Par‐4 is
downregulated during differentiation (Boghaert et al., 1997). Aligned with the fact that
Par‐4 is an apoptotic protein, its expression is increased during development in actively
dying cells, such as the interdigitating web cells of the mouse embryo and the involuting
tadpole tail. Par‐4 also plays a key role in neuronal development, where an increase in
Par‐4 levels results in apoptosis and serves to maintain the number of neurons in the
nervous system (El‐Guendy and Rangnekar, 2003).

The Par‐4 gene produces a 38‐kDa protein consisting of 332 amino acids. This
protein has a variety of interesting structural domains that allude to its potential
mechanism of action. Par‐4 has a 42‐residue leucine zipper domain in its C‐terminus,
along with a nuclear export sequence (NES).

Two putative nuclear localization

sequences (NLS) are present in the amino‐terminus, and both NLS are highly conserved
in the Par‐4 protein among different species. In addition, Par‐4 possesses a number of
conserved consensus sites for phosphorylation by kinases, such as PKA and PKC (Figure
1.2). Collectively, the presence of these motifs suggests that the function of Par‐4 may
be tightly regulated by post‐translational modification, localization, and dimerization
with partners of biological consequence.

Pro‐apoptotic role of Par‐4
The role of Par‐4 in apoptosis has been well studied in cell culture models.
Overexpression studies have revealed that an increase in Par‐4 level or activity in
normal or immortalized cells results in a lowered sensitivity threshold to death stimuli
(such as growth factor withdrawal, elevation of intracellular Ca2+, TNF‐α, IFNγ, or UV, X‐
ray, and gamma irradiation). In addition, Par‐4 has been found to be an essential
downstream regulator of cell‐death programs initiated by different agents such as
TRAIL, vincristine, doxorubicin, and radiation. In transformed cells, Par‐4 is capable of
initiating the death program in the absence of a second stimulus. Interestingly, strong
oncogenic or growth‐promoting factors render tumor cells susceptible to Par‐4‐induced
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Figure 1.2 : Domain Structure and Phosphorylation Sites of Par‐4

CK2 PKC PKA

PKC Akt

1

332
20

25

137

NLS1

153

290

NLS2
137

332
LZ

SAC

11

195

Figure 1.2 : Schematic representation of the Par‐4 protein domain structure and
phosphorylation sites :

The domains NLS1 (nuclear localization sequence), NLS2, SAC and leucine zipper (LZ) are
represented by filled brackets underlining the region. Phosphorylation sites are indicated by
bars – activating phosphorylation in red (PKA), inactivating modification in green (Akt) and
phophorylation sites of unknown function in black (PKC & CK2).
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apoptosis. This ability of Par‐4 to effect apoptosis exclusively in cancer cells is intriguing
and indicates that Par‐4 has merit as a potent therapeutic tool.

While most studies have focused on ectopic overexpression of Par‐4, under
specific conditions endogenous Par‐4 expression is also powerful as an apoptotic agent.
Beyond the aforementioned role of Par‐4 in the tadpole tail and interdigitating web,
Par‐4 plays a role in neuronal apoptosis during embryonic development and serves to
prevent hyperproliferation of nerve tissue (El‐Guendy and Rangnekar, 2003). This is
achieved by the asymmetric distribution of Par‐4 protein during the mitosis of neuronal
progenitor cells; the daughter cells lacking Par‐4 differentiate into neurons, while those
with high levels of Par‐4 undergo apoptosis (Bieberich et al., 2003). A recent study
demonstrated that this function of Par‐4 can be exploited during neural transplant to
beget selective apoptosis of pluripotent stem cells and enrich the neuronal precursors
among this population of embryonic stem cells (Bieberich et al., 2004).

It is well established that normal physiological processes can become skewed
during the onset of a disease and thereby augment the disease process. Several
observations support the fact that Par‐4 is also involved in the development of
neurodegenerative disorders by increasing the apoptosis of healthy neurons. First,
elevated levels of Par‐4 mRNA and protein have been observed in the apoptotic neurons
of patients, animal models, and cell culture models of diseases such as Alzheimer's,
Parkinson's, Huntington's chorea, amyotrophic lateral sclerosis (ALS), and ischemic brain
injury or stroke (El‐Guendy and Rangnekar, 2003; Mattson et al., 1999). Second, Par‐4 is
also thought to facilitate the development of such degenerative conditions by inhibiting
the uptake of choline at the cholinergic synapse (Xie and Guo, 2004). Finally, it was
recently reported that Par‐4 is involved in the regulation of the protease that cleaves
the amyloid beta precursor protein to give Aβ peptide, the key pathogenic protein in
Alzheimer's (Xie and Guo, 2005).
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In addition to apoptosis, Par‐4 has been identified as playing a non‐apoptotic
role in various cell types. One such example is the role of Par‐4 in the modulation of
immune response by keeping in check the secretion of IL‐2 and other important
immunomodulatory cytokines (Lafuente et al., 2003).

Mechanism of apoptosis by Par‐4
Programmed cell death usually occurs through one of the two major signaling
pathways, known as the extrinsic and the intrinsic pathway. The extrinsic pathway
proceeds through death receptors while the intrinsic pathway is mediated by the
mitochondria. The extrinsic pathway is initiated at the cell surface via the activation of
transmembrane death receptors of the CD95 (Apo‐1 or Fas)/TRAIL/tumor‐necrosis
factor (TNF) receptor 1 family. Engagement of these receptors with their cognate ligand
triggers the assembly of a multiprotein complex that activates the upstream caspase 8.
In the intrinsic pathway, reception of a stress/death signal is transduced to the
mitochondria, which in turn release cytochrome c into the cytosol; this results in the
formation of the apoptosome complex to activate caspase 9. Caspases 8 and 9 both
activate downstream effector caspases that carry out the final steps of apoptosis, such
as release of the endonuclease CAD (caspase‐activated DNAase) from its inhibitor iCAD
and cleavage of key cellular enzymes and proteins (Strasser et al., 2000). Although the
intrinsic and extrinsic pathways ultimately converge at the level of the effector caspases,
molecular cross talk between the two pathways is known to exist. A number of
factors—both pro‐apoptotic factors that drive the cell toward suicide and pro‐survival
proteins that protect the cell from death—are involved in regulating apoptosis at each
level of this signaling cascade.

Since Par‐4 is a pro‐apoptotic protein, it sets the cell‐death program in motion by
acting at two levels: the activation of molecular components of the cell‐death machinery
and the inhibition of pro‐survival factors. Par‐4, as characterized to date, appears to act
through the extrinsic pathway by enabling the trafficking of Fas and Fas ligand to the
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plasma membrane. Fas/CD95 is a member of the TNF‐R family and is activated by
binding to Fas ligand. Such binding leads to the formation of a complex consisting of
trimeric Fas, the adaptor protein FADD (Fas‐associated death domain) and pro‐caspase
8; this complex is called the death‐inducing signaling complex, or DISC. The formation of
DISC in turn leads to the cleavage and activation of the zymogen, pro‐caspase 8, to its
active caspase form. Interestingly, Par‐4 translocates Fas and FasL to the plasma
membrane in androgen‐independent cancer cells, in which overexpression of Par‐4
leads directly to death. However, the same effect is not observed in the androgen‐
dependent cancer cells, wherein Par‐4 serves only to sensitize. The mechanism of
apoptosis when Par‐4 has a sensitizing effect may involve the intrinsic pathway or may
vary depending on the second signal (Chakraborty et al., 2001).

As previously mentioned, in addition to its effect on the extrinsic pathway, Par‐4
also plays a very important role in antagonizing the pro‐survival/anti‐apoptotic factors
that present a major obstacle to the apoptosis cascade. One of the most important anti‐
apoptotic factors active in a cell is the transcription factor NF‐κB.

NF‐κB is a

heterodimer consisting of p65 (RelA) and p50 subunits. This dimer is held inactive in the
cytoplasm as a result of being bound to the inhibitory protein IκB, which on the
appropriate signal is phosphorylated by IKKβ, ubiquitinated, and ultimately degraded to
release an active NF‐κB. Following other phosphorylation events and translocation into
the nucleus, the active NF‐κB transcription factor binds to the promoter of its target
genes and regulates transcription. One of the very important anti‐apoptotic targets of
NF‐κB is the XIAP (X‐linked inhibitor of apoptosis), which hinders the activity of both
upstream and effector caspases (Baldwin, 1996; Barkett and Gilmore, 1999). Par‐4
inhibits NF‐κB activity and this Par‐4‐mediated inhibition of NF‐κB is carried out without
disrupting the DNA‐binding capacity of the NF‐κB complex. It is proposed that Par‐4 acts
in the nucleus to inhibit phosphorylation of NF‐κB by IKKβ or PKCζ, which would
otherwise confer maximal activity to NF‐κB.

In addition, interference with IKKβ

phosphorylation of the IκB complex in the cytoplasm acts as another molecular
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safeguard against the activation of NF‐κB (Diaz‐Meco et al., 1999). This ability of Par‐4
to inhibit pro‐survival factors might be essential to its apoptosis‐sensitizing function.

Cancer Antagonism by Par‐4
Consistent with its role in apoptosis, Par‐4 has a tumor‐suppressive function.
Although the function of Par‐4 in apoptosis is an important component of a cell's anti‐
transformation surveillance (Hanahan and Weinberg, 2000), Par‐4 also exerts
considerable influence in its tumor‐ suppressive role. In support of its role in tumor
suppression, Par‐4 is downregulated in a variety of cancers, such as renal‐cell
carcinomas, neuroblastoma, acute lymphoblastic leukemia, and chronic lymphocytic
leukemia (Boehrer et al., 2001; Gurumurthy and Rangnekar, 2004). Moreover, Par‐4
mRNA and protein are downregulated by oncogenic Ras in a variety of cell types
through the MEK‐ERK pathway (Barradas et al., 1999; Qiu et al., 1999b).

This

downregulation is necessary for Ras to initiate transformation because ectopic
overexpression of Par‐4 in Ras‐transformed cells impedes formation of colonies in a soft
agar assay (Qiu et al., 1999b). This anti‐transformation effect may be attributed to the
fact that Par‐4 antagonizes the Ras‐MAPK pathway by repressing ERK, an essential
downstream kinase in this pathway (Qiu et al., 1999b). This function of Par‐4 is
independent of its pro‐apoptotic ability although oncogenic Ras is known to sensitize
cells to apoptosis by Par‐4 (Nalca et al., 1999). Despite being down regulated by Ras in
certain cell types, Par‐4 is present at copious amounts in most cancer cells unlike a few
tumor suppressors yet, is functionally inactivated by the cell survival kinase Akt. Binding
and phosphorylation of Par‐4 by Akt creates a binding site for the adapter protein 14‐3‐
3θ. Par‐4 is mislocalized to the cytoplasm and sequestered away from its site of action
by interaction with 14‐3‐3θ during transformation for unchecked survival and
proliferation (Goswami et al., 2005).

In addition to inhibiting transformation, Par‐4 plays a role in tumor regression;
hence, Par‐4 is antagonistic to both tumor formation and tumor maintenance.
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Subcutaneous tumors, which were generated in nude mice using PC‐3 cells, regressed in
less than 3 weeks after a single injection of Par‐4 adenovirus (Chakraborty et al., 2001).
In

another

study,

Par‐4

overexpression

decreased

tumor

development

in

xenotransplants of A375‐C6 melanoma cells in mice; tumor reduction was due to an
increase in apoptosis (Lucas et al., 2001). This effect of Par‐4 is due to its pro‐apoptotic
function because both activation of the Fas pathway and inhibition of NF‐κB are
essential for tumor regression (Chakraborty et al., 2001). Tumors expressing either dn‐
FADD (an inhibitor of the Fas pathway) or RelA (resulting in an active NF‐κB) are
resistant to the tumor‐regressive effects of Par‐4 (Chakraborty et al., 2001). Par‐4 has
been recently implicated in the suppression of tumors in hematopoietic stem cells by
disrupting the BCR‐Abl signaling pathway (Kukoc‐Zivojnov et al., 2004). In addition, Par‐
4 may be a player in the control of metastasis as well because Par‐4 inhibited the
migration of B16F1 melanoma cells by acting as a negative regulator of PKC kinase
activity (Sanz‐Navares et al., 2001). Most importantly, the Par‐4 knockout mice display a
high predisposition to formation spontaneous and induced tumors, especially of the
prostate, endometrium, lung and liver (Garcia‐Cao et al., 2005).

Moreover, Par‐4

interacts with and regulates the function of Topoisomerase I in normal cells. Disruption
of this function of Par‐4, as during transformation by inactivation of Par‐4, affords the
cell unimpeded access to topoisomerase activity, which is thoroughly exploited to
provide for the proliferative demands of the transformed state (Goswami et al., 2008).
Collectively, the data discussed above validate Par‐4 as a viable target for therapeutic
intervention in cancer treatment.

Regulation of Par‐4 function
Given the pro‐apoptotic function of Par‐4, it is essential for the cell to tightly
regulate its activity, thereby keeping Par‐4 in a dormant state and activating it only
when necessary. Consequently, regulation is managed by localizing Par‐4 to distinct
cellular compartments. It was observed during Par‐4 overexpression studies that Par‐4
is translocated to the nucleus well before the cell undergoes apoptosis. Inhibition of
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nuclear entry abrogated the apoptotic potential of Par‐4. As mentioned earlier, Par‐4
contains two putative NLS at its amino‐terminus. A deletion mutant that lacks both of
these nuclear localization sequences is incapable both of nuclear entry and promoting
apoptosis. Additional deletion analysis indicated that the first NLS (NLS1) was not
necessary for nuclear entry and that the second NLS (NLS2) plays an important role in
nuclear translocation. Consistent with these results, it was observed that in androgen‐
dependent cancer cells (in which Par‐4 is unable to induce apoptosis), Par‐4 is
predominantly localized in the cytoplasm. In contrast, nuclear localization of Par‐4 is the
norm in androgen‐independent cancer cells, as well as many other cancer cells; in these
cells, Par‐4 has a lethal effect. The functional role of the nuclear export sequence
present in the C‐terminus has yet to be elucidated. Furthermore, there are substantial
data indicating the presence of Par‐4 in the PML bodies (promyelocytic leukemia bodies)
of the nucleus. Although the significance of this localization remains to be clarified, it is
possible that the Par‐4 mechanism of apoptosis specifically resides in the PML bodies
(Gurumurthy and Rangnekar, 2004). Control of Par‐4 function cannot be ascribed to the
regulation of its localization alone and, as explained below, there are additional
mechanisms through which its activity is monitored.

Par‐4 that is present in the cytoplasm is partnered with various proteins, and
many of the functions of Par‐4 can be attributed to the effect of these interactions. One
of the very important and extensively studied partners of Par‐4 is the kinase, PKCζ (Diaz‐
Meco et al., 1996). Par‐4 binds to PKCζ and inhibits its major functions, not the least
among them being activation of NF‐κB. PKCζ‐induced activation of NF‐κB is lost in the
presence of equal or excess amounts of Par‐4. This effect on PKCζ is the key to NF‐κB
inhibition by Par‐4, although this does not preclude the existence of other mechanisms.
To add further complexity to this equation, another protein, p62, is sometimes bound to
the Par‐4/ PKCζ complex. When p62 interacts with the Par‐4/ PKCζ complex, the effect
of Par‐4 on PKCζ is lost and, as a result, cell survival is promoted (Chang et al., 2002b).
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Another important partner for Par‐4 is the Wilms' tumor protein, WT‐1
(Johnstone et al., 1996). WT‐1 is a transcription factor that possesses a zinc finger and
acts as either an activator or repressor for many growth factor genes. WT‐1 protein is
expressed during development in the kidney, testis, and ovary and plays an important
role in the development of Wilms' tumor, as its name suggests. WT‐1 induces the
transcription of the anti‐apoptotic protein Bcl2; this transcriptional activity is inhibited
when Par‐4 is bound to WT‐1. Par‐4, along with WT‐1, binds to the promoter of Bcl2,
inhibits transcription, and thereby promotes apoptosis (Qiu et al., 1999a).

Par‐4

regulates the function of WT‐1 during the transcription of other genes as well; however,
the significance of these regulations has yet to be studied.

Par‐4 also binds to ZIP kinase (also known as ZIPK or DLK) in the PML bodies.
This interaction is necessary for ZIPK‐induced apoptosis because Par‐4 promotes
interactions between ZIPK and DAXX, which is a regulator of apoptosis (Page et al.,
1999). In addition, Par‐4 complexes with THAP‐1, a pro‐apoptotic protein that is also
associated with the PML subnuclear bodies (Roussigne et al., 2003). These Par‐4
interactions with ZIPK, DAXX, and THAP‐1 all function to catalyze apoptosis, and it is
likely that these associations are mediated by the C‐terminal leucine zipper domain of
Par‐4, which is essential for the pro‐apoptotic function of this protein (Sells et al., 1997).
Beyond the binding interactions detailed here, there may be other binding partners of
Par‐4 for which identity and function are yet to be elucidated.

Cancer Selective Apoptosis
Since Par‐4 is subject to regulation at multiple levels, a study was undertaken to
identify the minimum region of Par‐4 essential for apoptosis induction, and this search
ultimately led to the discovery of Par‐4's remarkably unique property of cancer‐selective
apoptosis. Deletion analysis was used to identify the minimum essential domain that
would facilitate apoptosis and yet be free of inhibitory interactions. Par‐4, which
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contains 332 amino acids, was progressively and selectively pared to make a variety of
small mutants. In the course of this study, a mutant comprising the region spanning
amino acids 137‐195 was identified as the core domain that orchestrates the apoptotic
function of Par‐4. Upon further deletion up to the amino acid 187 (thus a fragment
consisting of amino acids 137‐187), the apoptotic function was lost.

It was also

observed that the small 137‐195 domain was constitutively nuclear and caused selective
apoptosis of cancer cells upon overexpression. Therefore, this 137—195 mutant is
called SAC for selective apoptosis of cancer cells (El‐Guendy et al., 2003). Moreover,
recently, transgenic mice over‐expressing the SAC module of Par‐4 proved to be “cancer
resistant” when crossed with the TRAMP (TRansgenic Adenocarinoma of Mouse
Prostate) mice, with a staggering 80% reduction in tumor incidence. In addition, these
mice were highly resistant to spontaneous tumors developed with age as well, further
supporting the tumor inhibitory function of Par‐4 (Zhao et al., 2007).

SAC, which localized to the nucleus both in normal and cancer cells, caused
apoptosis only in cancer cells when overexpressed. This led to the conclusion that, in
addition to nuclear entry, an activating event that is present only in cancer cells is
necessary for Par‐4 to attain its full apoptotic potential. The SAC region contains a few
phosphorylation sites, and so the possibility of phosphorylation as a potential regulator
was studied. Two amino acids, a serine at 154 and a threonine at 155 are consensus
sites for PKA (protein kinase A). PKA is a universal kinase that phosphorylates a wide
range of substrates that are involved in the regulation of metabolism, cell growth, and
differentiation.

Elevation of intracellular levels of cAMP (cyclic adenosine

monophosphate) results in the activation of PKA and the transduction of a signal
downstream via phosphorylation. PKA occurs in two isoforms, I and II, depending on
the regulatory subunit that is associated with the kinase. Isoform I is overexpressed in
human cancer cells and primary tumors and, consequently, the PKA enzymatic activity is
higher in transformed cells than in normal or immortalized cells (Tortora and Ciardiello,
2002). This enhanced PKA activity may explain the cancer‐specific activation of Par‐4.
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Indeed, further studies revealed that phosphorylation by PKA is a crucial event that
triggers the apoptotic function of Par‐4; in the absence of this phosphorylation, Par‐4
completely lost its ability to effect apoptosis.

To further clarify the regulation of Par‐4, the PKA consensus serine (154) and
threonine (155) were individually mutated to alanine in order to eliminate
phosphorylation at these sites. It was found that a mutation at the 155 residue
abolished apoptosis by Par‐4, while the Par‐4‐154A mutant retained its apoptotic ability.
SAC with 155 mutated, although still nuclear in localization, was unable to kill
transformed and androgen‐independent cell types such as NIH3T3/Ras, lung cancer cells
A549, H460, H157, and H838 and breast cancer cells MCF‐7, MDAMB‐231, and MDAMB‐
435. Phosphorylation of ectopically expressed Par‐4 by PKA has been confirmed by
metabolic labeling, while phosphorylation of endogenous Par‐4 has been established
using an antibody raised against the phospho‐threonine residue at 155.

These

experiments reveal that Par‐4 is phosphorylated in its active state and that this
phosphorylation event is very common in cancer cells when compared to normal cells.
Additional experiments, including the inhibition of phosphorylation of Par‐4 (and thus
apoptosis) with an inhibitory peptide and the provision of cAMP to normal cells in order
to make them susceptible to apoptosis by Par‐4, support the fact that Par‐4 is controlled
at several levels in the cell (Gurumurthy et al., 2005).

Par‐4‐inducible apoptosis can now be explained by the model that Par‐4 requires
two distinct events—specifically, nuclear entry and phosphorylation by PKA—for
activation. Both regulating events are present and active in cells that display sensitivity
to Par‐4. In cells that are resistant to Par‐4, such as hormone‐dependent cancer cells
and normal or immortalized cells, one or both of these activating events are absent,
and, despite the presence of substantial amounts of Par‐4, the cells remain resistant to
apoptosis (Figure 1.3).

21

Figure 1.3 : Cell type specific regulation of Par‐4
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Figure 1.3 : Model for cell type specific regulation of Par‐4 :

Two independent events are necessary to activate Par‐4—nuclear entry and
phosphorylation by PKA. In normal or immortalized cells, owing to low levels of active
PKA, Par‐4 is not phosphorylated at the T155 residue; in addition, it is retained in the
cytoplasm by an unknown mechanism, and hence Par‐4 is inactive. In cancer cells that are
resistant to apoptosis by Par‐4, despite phosphorylation at the T155 residue, Par‐4 is
inhibited from entering the nucleus by Akt‐1. In cancer cells sensitive to Par‐4, it is
phosphorylated by PKA at T155 and the inhibition by Akt‐1 is absent. Par‐4, which is thus
activated by phosphorylation and nuclear entry, causes apoptosis of cancer cells.
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Although studies so far have revealed much about the regulation and the
mechanism of action of Par‐4, it is likely that Par‐4 acts in more complex ways than can
be accounted for by the pathways detailed thus far. Par‐4 is clearly emerging as a tumor
suppressor that would be ideal for therapeutic intervention strategies, keeping in mind
that each small effort, as is the case with all cancer research, takes us one step closer to
understanding the genesis of cancer and the ultimate goal of developing a superior
oncotherapy.
[Par‐4 portion adapted with permission from (Ranganathan and Rangnekar, 2005)]
Caspase‐8
Caspases, as mentioned earlier, are a family of cysteinyl endopeptidases that are
the primary executioners of programmed cell death. As an initiator caspase, caspase‐8
is at the head of the extrinsic cascade hierarchy. The human caspase‐8 gene is located
on chromosome 2q33 (Earnshaw et al., 1999). Caspase‐8 is synthesized as an inactive
zymogen with a long amino terminal pro‐domain that contains two Death Effector
Domains (DED), and two catalytic subunits, which are approximately 20kd and 10kd in
size.

The DEDs mediate hydrophobic interactions with additional pro‐caspase‐8

molecules and other DED containing proteins such as the adaptor FADD.

Caspase‐8 is activated primarily along the receptor mediated extrinsic pathway.
Binding of death ligands to their respective receptors initiates the formation of the
multi‐protein DISC which provides a molecular platform for caspase‐8 activation. The
cell surface death receptors capable of activating caspase‐8 include Fas/CD95/Apo‐1,
TNFR (Tumor Necrosis Factor α Receptor), DR‐3/Apo‐3, DR‐4 and DR‐5 (Death Receptor‐
4/ Death Receptor‐5), and NGFR (Nerve Growth Factor Receptor) (Ashkenazi and Dixit,
1998). The functional DISC consists of a trimerized, ligand bound receptor, adapter
proteins TRADD (TNFR Associated Death Domain) and/or FADD, and the pro‐caspase‐8
zymogen. Pro‐caspase‐8 is activated in the DISC by dimerization and the active enzyme
is released into the cytosol following proteolytic auto‐processing of the N terminal pro‐
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domain. The active caspase‐8 enzyme is a heterotetrameric complex consisting of two
large (20kd) and two small (10kd) subunits with two active sites for each complex.
Caspase‐8 may also be activated unconventionally by caspase‐6 mediated processing in
the final stages of the apoptotic program, contributing to the amplification loop
(Cowling and Downward, 2002). The activated caspase‐8 primarily cleaves and activates
caspase‐3, the effector caspase that is responsible for most of the phenotypic changes
of apoptosis, in certain cell types, for instance, lymphocytes, which are termed as type I.
In other types of cells, such as hepatocytes, the meager caspase‐8 activated at the DISC
cleaves Bid, which then induces cytochrome c release from the mitochondria (Ozoren et
al., 2000). Cytosolic cytochrome c aids in activation of initiator caspase‐9, which cleaves
and activates caspase‐3 (Li et al., 1997) (Figure1.1). Caspase‐8 is also capable of
activating caspases ‐1, ‐2, ‐6, ‐7, ‐9 and ‐11, in addition to caspase‐3 (Van de Craen et al.,
1999).

Additionally, the activated caspase‐8 cleaves certain non‐caspase substrates

such as PAK2 (p21 Activated Kinase), Wee1 kinase, FLIPL (Earnshaw et al., 1999), and
plectin (Stegh et al., 2000), to carry out its apoptotic as well as non‐apoptotic functions.

Caspase‐8 activation can be regulated by several proteins such as FLIP, BAR, ARC,
p35 (baculoviral origin), and CrmA (cowpox virus protein). FLIP exists in two forms, a
short one (FLIPS) and a long one (FLIPL). FLIPS contains two DEDs, while the longer FLIP
has a non‐functional caspase like domain in addition to the DEDs. FLIPS inhibits caspase‐
8 activation by virtue of the death effector domains that bind with high affinity to the
DISC in place of pro‐caspase‐8. FLIPL, on the other hand, is known to both activate
caspase‐8, by perhaps assisting dimerization of pro‐caspase‐8 molecules, and at times,
inhibit, depending on the prevailing conditions (Chang et al., 2002a). BAR (Bifunctional
Apoptosis Regulator) contains a DED and impedes caspase‐8 activation by competing
with FADD for binding to pro‐caspase‐8 (Zhang et al., 2000). ARC (Apoptosis Repressor
with CARD) interacts with caspase‐8 and inhibits its activation in a manner similar to
BAR, however, owing to the fact that the protein has a CARD instead of a DED, the
mechanism of action is not fully understood (Koseki et al., 1998).

25

Caspase‐8 mediated apoptosis is essential for embryonic development as
demonstrated by the knockout, which exhibited embryonic lethal phenotype owing to
defects in extra‐embryonic yolk sac vasculature, cardiac development and endothelial
cell homeostasis (Varfolomeev et al., 1998).

In addition to these well recognized

apoptotic functions, caspase‐8 also plays a role in the expansion of hematopoietic
progenitors in the bone marrow, T cell activation and development (Kang et al., 2004;
Salmena et al., 2003). Furthermore, it plays a role in cell motility by regulating Rac and
Calpain activation for lammellipodial assembly (Helfer et al., 2006).

Caspase‐8 is vital to the initiation of a rapid death cascade that it is predictably
inactivated in a number of cancers. Caspase‐8 protein expression is decreased due to
various causes in childhood neuroblastomas, renal cell carcinoma, Small Cell Lung
Carcinoma (SCLC) and certain Non‐Small Cell Lung Carcinomas (NSCLC) (Shivapurkar et
al., 2002; Teitz et al., 2000). Caspase‐8 is mutated in 5% of all invasive colorectal
carcinomas (Kim et al., 2003), and is mutated in cell lines of head and neck cancer
(nonsense), neuroblastoma (missense) and vulvar squamous carcinoma (deletion)
(Philchenkov et al., 2004). In general, the level of expression of this protein is decreased
in cancer cell lines and neoplastic tissues when compared to control or surrounding
normal tissue.

In addition to such inactivations, the caspase‐8 promoter is

hypermethylated in several neuroblastomas, rhabdomyosarcomas, meduloblastomas,
retinoblastomas, and human hepatocellular carcinomas (Harada et al., 2002; Yu et al.,
2002). Moreover, in neuroblastomas, metastasis is permitted by loss of caspase‐8,
owing to its function in cell motility (Stupack et al., 2006).

Caspase‐8 is an emerging target of cancer gene therapy and both in vitro and in
vivo studies have demonstrated its tumoricidal efficacy.

Adenoviral vector based

expression of caspase‐8 potentiated both x‐ray and 5‐fluorouracil induced apoptosis in
colon cancer cells (Uchida et al., 2003). Growth inhibition of subcutaneously established
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tumor of glioblastoma in mice by augmented expression of caspase‐8 from the hTERT
promoter further underscores the value of caspase‐8 in apoptosis based tumor
suppression. Hence, characterization of realistic, non‐toxic means of inducing intrinsic
caspase‐8 activity in the cancer cell is an important goal in the development of cancer
therapies.

TRAIL
TNF Related Apoptosis Inducing Ligand (TRAIL /Apo2L), a member of the TNF
family of cytokines, induces apoptosis specifically in the cancer cells while remaining
relatively non‐toxic to normal cells. Recombinant TRAIL causes tumor regression and
reduces tumor incidence in murine cancer models (Ashkenazi et al., 1999; Walczak et
al., 1999) and is currently in phase I clinical trial (Ashkenazi and Herbst, 2008),
(www.cancer.gov). Despite being such a promising candidate for therapeutic usage,
mechanistic details of the signal transduction pathways that lead to TRAIL resistance
and sensitivity have not been studied extensively.

TRAIL is expressed as a type II transmembrane protein that can signal as an
intact protein in situ, or generate by proteolytic cleavage, an extracellular domain to be
utilized in signaling to surrounding cells. This ligand forms a homotrimer that can bind
to any of its five designated receptors, two of which are apoptotic. DR4/TRAIL‐R1 and
DR5/TRAIL‐R2, with a functional death domain (DD) in the intracellular region, transduce
the apoptotic signal upon ligand binding. DcR1/TRAIL‐R3, DcR2/TRAIL‐R4, and the
soluble receptor OPG (Osteoprotegerin), lack functional death domains and serve as
decoy receptors to inhibit apoptosis (Almasan and Ashkenazi, 2003). Binding of TRAIL to
either DR4 or DR5 permits recruitment of the adaptor protein FADD and initiator
caspase‐8 to the receptor. FADD binds to the receptor through its DD (Death Domain)
and to caspase‐8 through DED (Death Effector Domain) to form the DISC (Death
Inducing Signaling Complex) (Kischkel et al., 2000; Sprick et al., 2000). Caspase‐8 is
activated in the DISC by dimerization (Boatright et al., 2003) and the active dimers are
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released into the cytosol by self cleavage at the N‐terminus. Caspase‐8 then directly
cleaves and activates caspase‐3 in the Type I cells. Whereas, in the Type II cells, the
minimal caspase‐8 that is activated cleaves Bid, which then induces cytochrome c
release from the mitochondria (Ozoren et al., 2000). Cytosolic cytochrome c aids in
activation of initiator caspase‐9, which cleaves and activates caspase‐3 (Li et al., 1997).
The effector caspase‐3 cleaves death substrates such as CAD (Caspase Activated DNAse),
PARP (Poly ADP Ribose Polymerase), fodrin, actin and lamin to complete apoptosis
(Kidd, 1998).

High levels of decoy receptor expression are found in most normal adult tissues,
possibly accounting for the resistance of normal cells to TRAIL. However, a strong
correlation between decoy receptor expression and resistance in cancers is not seen.
Similarly, FLIP (FLICE Inhibitory Protein), the non‐catalytic homolog of caspase‐8, is
expressed at high levels in certain TRAIL resistant cancer lines, which can be sensitized
by inhibiting protein synthesis or by activating proteosome based degradation of FLIP.
Additionally, in the Type II cells, high levels of IAP (Inhibitor of Apoptosis Protein) can
inhibit the caspase cascade by interfering with the activation and activity of caspases‐9
and ‐3. In terms of inhibiting apoptosis, NF‐κB pathway can also be implicated as pro‐
survival proteins, such as FLIP, XIAP and Bcl‐Xl are induced in response to NF‐κB
activation. However, NF‐κB is not significantly stimulated in response to TRAIL even if
only in response to high concentrations of the ligand (Almasan and Ashkenazi, 2003).

Research objectives
Par‐4 is a protein that specifically targets cancer cells for apoptosis upon over
expression. Prior to this study, the data demonstrated only of the effects of Par‐4 under
conditions of artificial over expression and the aim of this work is to characterize the
function, if any, of the abundant endogenous Par‐4 with regard to apoptosis. The TRAIL
pathway was used as a model for this study due to the fact that TRAIL shares the
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features of cancer specific toxicity with Par‐4. In specific, this study has addressed the
following issues in two chapters:

Chapter 2 – Regulation of Caspase‐8 by Par‐4

1. Whether Par‐4 is involved in and is an integral component of the apoptotic
cascade initiated by TRAIL
2. Whether Par‐4 plays a role in activation of any of the caspases in response to
TRAIL
3. The mechanism of Par‐4 mediated caspase‐8 activation

Chapter 3 – Regulation of Par‐4 by Caspase‐8

1. The impact TRAIL signaling has on Par‐4.
2. Whether Par‐4 is a substrate of caspases activated by TRAIL and the identity of
the specific caspases involved.
3. The sites of cleavage in Par‐4 and the regulation of cleavage by phosphorylation.
4. Whether the caspases involved co‐operate to naturally generate the highly
potent functional core of Par‐4.

Copyright © Padhma Ranganathan 2008
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Chapter Two

Regulation of Caspase‐8 activation by Par‐4 in response to TRAIL
Introduction
TNF Related Apoptosis Inducing Ligand (TRAIL / Apo2L), a member of the TNF
family of cytokines, induces apoptosis specifically in cancer cells while remaining
relatively non‐toxic to normal cells. Recombinant TRAIL causes tumor regression and
reduces tumor incidence in murine cancer models (Walczak et al., 1999), and is
currently in Phase I clinical trials (www.cancer.gov). TRAIL initiates death signaling by
binding to either of its two functional receptors, DR4 or DR5; binding is followed by
activation of the initiator caspase‐8, at the receptor‐associated DISC (death inducing
signaling complex), followed by effector caspase‐3 activation to induce apoptosis (Plati
et al., 2008). Cells are categorized as type I or type II, depending on the initiator caspase
(i.e., either caspase‐8 or caspase‐9) that activates caspase‐3. In the type I cells, profuse
activation of caspase‐8 at the membrane results in caspase‐3 activation; on the other
hand, in type II cells, the insufficiently activated caspase‐8 induces activation of caspase‐
9, via t‐Bid‐mediated mitochondrial cytochrome c release (Ozoren and El‐Deiry, 2002).
Although TRAIL can be a very valuable therapeutic tool owing to its selective toxicity to
cancer cells, a number of tumors and cancer cell types acquire resistance to TRAIL,
limiting its clinical use. Sensitivity to TRAIL is modulated by a number of factors, such as
increased levels of decoy receptors, FLIP (FLICE inhibitory protein), expression of anti‐
apoptotic Bcl‐2 family members and IAP, and enhanced activity of NF‐κB; each of these
proteins targets a distinct stage of the apoptotic pathway (Almasan and Ashkenazi,
2003). I report here that prostate apoptosis response‐4 (Par‐4) is crucial for apoptosis
downstream of TRAIL, as activation of caspase‐8 following receptor engagement is
regulated by Par‐4.
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Par‐4 is a unique pro‐apoptotic protein, which, upon ectopic over‐expression,
selectively induces apoptosis in transformed cells, but not in normal or immortalized
cells (Ranganathan and Rangnekar, 2005).

Two activating events responsible for

susceptibility to Par‐4‐induced apoptosis are nuclear translocation of Par‐4 and
phosphorylation by PKA (Protein Kinase A). Indeed, phosphorylation of Par‐4 at a critical
residue by PKA accounts for the cancer selective apoptotic property of Par‐4
(Gurumurthy et al., 2005). Par‐4 is inactivated during tumorigenic transformation by a
number of mechanisms, which include down‐regulation by oncogenes, mislocalization
and functional inactivation by the pro‐survival kinase Akt (Goswami et al., 2005),
deletion of the Par‐4 chromosomal region, Par‐4 promoter methylation, and nonsense
mutation (Ranganathan and Rangnekar, 2005). Here, I report Par‐4 is an essential
component of the apoptotic cascade induced by TRAIL as Par‐4 is intimately involved in
activation of caspase‐8 at the DISC during death receptor signaling.

Materials and Methods
Cell lines and reagents
Non small cell lung carcinoma cell H460 and, colon carcinoma cells, SW480 and
HCT116, were purchased from ATCC, and cultured as per instructions. PC‐3 cells have
been previously described (Gurumurthy et al., 2005).

TRAIL was purchased from

Calbiochem.

Plasmids, small interfering RNA (siRNA) and transfection
Expression constructs for GFP, Par‐4‐GFP, and Par‐4/155A‐GFP, which acts as a
dominant negative mutant of Par‐4, ΔZip‐GFP and 1‐204‐GFP were previously described
(El‐Guendy et al., 2003). Another dominant negative Par‐4 mutant (DN‐Par‐4) was
generated by PCR amplification of the region encoding amino acids 240‐332 using rat
Par‐4

cDNA

as

the

template
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and

the

primers

(forward)

5’CCGAATTCGAATGGCAGGCTTCAGTAGA3’

and

(reverse)

5’CCGGTACCCTTGTCAGCTGCCCAACA3’. The primers included built‐in EcoR I (forward)
and Kpn I (reverse) sites (underlined). The amplified DNA fragment was cloned into
pEGFP‐N1 (EGFP, enhanced green fluorescent protein; Clontech) using the restriction
enzymes mentioned above to generate DN‐Par‐4‐GFP, with the EGFP tag at the C‐
terminus. Duplexes representing siRNA for Par‐4 (L‐004434‐00) and a non‐targeting
control (D‐001210‐01) were from Dharmacon, Inc. Cells were transiently transfected
with the indicated plasmids using lipofectamine reagent (Invitrogen Life Technologies,
CA) as per manufacturer’s instructions, and appropriately processed 24 hours later. For
RNA‐interference, siRNA duplexes were transfected using Lipofectamine 2000
(Invitrogen Life technologies, CA) according to manufacturer’s instructions for 72 hours
before the indicated treatment.

Western blot and antibodies
Cells were harvested and subjected to SDS‐PAGE followed by Western blot
analysis using appropriate antibodies (Vasudevan et al., 2006). Antibodies for Par‐4 (sc‐
1807), FADD (sc‐5559), caspase‐8 (sc‐7890 and sc‐5263), DR5 (sc‐65314), Sodium
Pottasium (Na+/K+) ATPase (sc‐28800) and caveolin‐1 (sc‐894) were from Santa Cruz
Biotechnology,Inc. Antibodies for cleaved caspase‐8 (9496), cleaved caspase‐3 (9664),
phospho‐Par‐4/T163 (2329), and DR5 (3696) were from Cell Signaling, Beverly, MA. The
antibody for actin was from Sigma‐Aldrich, St. Louis, MO. HRP conjugated secondary
mouse (NA931) and rabbit (NA934) antibodies were from Amersham/GE Healthcare,
Buckinghamshire, UK.

Apoptosis assay and immunocytochemistry
Cells plated in chamber slides, were transfected with siRNA duplexes (for control
or Par‐4) or plasmids (expressing GFP control, Par‐4‐155A‐GFP, or DN‐Par‐4‐GFP),
treated with TRAIL, and formalin fixed after the indicated times.
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The cells were

subjected to immunocytochemistry for Par‐4, caspase‐8, FADD, caveolin‐1, ATPase or
DR5 (sc‐65314) with the respective antibodies, followed by secondary antibody
conjugated to Alexa Fluor 488 (green fluorescence) or Alexa Fluor 594 (red fluorescence)
from Molecular Probes, Invitrogen. Nuclei were stained with DAPI (4, 6, diamidino‐2‐
phenyl indole for cyan fluorescence) from Vector Laboratories, Inc., Burlingame, CA.
The cells were visualized via confocal, fluorescent microscopy to examine either co‐
localization, or nuclear condensation (a marker for apoptosis). A minimum of 200 cells
were scored for apoptosis in each experiment, which was performed at least three
times (Gurumurthy et al., 2005).

Caspase activity assay
Caspase‐8 activity was assayed using CaspGLOW Red Active caspase‐8 staining
kit (K198‐25) from Biovision, Inc., according to manufacturer’s instructions. Cells were
assayed in a 96‐well plate, and fluorescence read at 570 nm.

Co‐immunoprecipitation
Cells were grown in 100‐mm plates and following treatment, the cells were lysed
for 20 mins in RIPA (Radio Immuno Precipitation Assay) buffer containing 10mM TRIS,
ph 7.5, 150mM Sodium Chloride, 1% Sodium deoxycholate, 1% Triton X‐100, 0.1% SDS
and appropriate amount of protease inhibitor cocktail, on ice. The cell lysates were
then centrifuged at high speed and the supernatant protein fraction was used for
further processing. The proteins of interest were immuno precipitated for with 2
micrograms of the respective antibodies per milligram of total protein for 3 hours,
followed by incubation with 75 microliters each of sepharose G beads (Amersham/GE
healthcare, Buckinghamshire, UK) for 1 hour. The immuno precipitates were then
washed thrice with RIPA buffer, boiled on SDS‐PAGE sample loading buffer and run on
SDS‐PAGE for western blotting.

33

Results
Par‐4 is a necessary component of TRAIL inducible apoptosis
I studied the requirement of Par‐4 for TRAIL signaling in various cell lines: PC‐3,
SW480, H460 and HCT116. Endogenous Par‐4 was silenced in these cells using siRNA
(Fig. 2.1 A & B), and the cells were incubated with TRAIL and assayed for apoptosis.
TRAIL induced apoptosis in each cell line tested, and this effect was attenuated by Par‐4
knockdown (Fig. 2.1 A & B). PC‐3 and SW480 are type I cells, while H460 and HCT116
generate a type II response to TRAIL, yet the effect of Par‐4 was not restricted to either
cell type. To further confirm that the loss of efficacy of TRAIL was a consequence of loss
of Par‐4 function, I transfected PC‐3 and SW480 cells with two distinct dominant
negative mutants of Par‐4: DN‐Par‐4‐GFP and Par‐4/155A‐GFP (Gurumurthy et al., 2005)
Following TRAIL treatment, I measured apoptosis, and noted it was significantly reduced
(P < 0.001) in the cells transfected with either one of the two dominant negative Par‐4
mutants (Fig. 2.1 C).

Par‐4 is necessary for activation of initiator caspase‐8
As Par‐4 is indispensable for apoptosis by TRAIL in both type I and type II cells, I
hypothesized Par‐4 must regulate a generic step common to both pathways. To identify
precisely the stage at which Par‐4 acts, I examined regulation of the downstream
effector, caspase‐3. I transfected PC‐3 cells with non‐specific siRNA or siRNA for either
Par‐4 or PKA and the cells were then incubated with TRAIL. I confirmed knock down of
both proteins by either Par‐4 expression or by PKA‐dependent phosphorylation of the
T163 residue on Par‐4 by Western blot analysis, since PKA activates Par‐4 by
phosphorylation (Gurumurthy et al., 2005) (Fig. 2.2). As seen in Fig. 2.2, caspase‐3 was
activated following TRAIL treatment in the non‐specific siRNA control cells, but was
inactive when either Par‐4 or PKA was silenced.
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Figure 2.1 : Loss of TRAIL apoptotic potential in the absence of Par‐4
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Figure 2.1 : Loss of TRAIL apoptotic potential in the absence of Par‐4
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Figure 2.1: Loss of TRAIL apoptotic potential in the absence of Par‐4.

A & B: Silencing of Par‐4 using siRNA inhibits TRAIL inducible apoptosis: Type I PC‐3
and SW‐480 cells (A), or type II H460 and HCT116 cells were transfected with a non
specific control or Par‐4 siRNA and 48hrs later treated with TRAIL for an additional
24hrs. Apoptosis was analysed by nuclear condensation using DAPI. The results
shown are a mean of three independent experiments and a representative western
blot is shown for each cell line showing Par‐4 knockdown with siRNA. The apoptosis
results were statistically analyzed using two way anova and significance when
compared to control is denoted by a * (p<0.001).
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Figure 2.1 : Loss of TRAIL apoptotic potential in the absence of Par‐4
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155A

Figure 2.1: Loss of TRAIL apoptotic potential in the absence of Par‐4.

C : Interfering mutants of Par‐4 inhibit apoptosis by TRAIL: PC‐3 and SW‐480 cells
were transfected with GFP, Dominant negative Par‐4 or Par‐4 155A constructs and
treated with TRAIL 24hrs later. Apoptosis was analyzed by nuclear condensation
using DAPI and the results were statistically analyzed using two way anova. The
results shown are a mean of 3 independent experiments and statistical significance is
denoted by * (p<0.001)
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I next examined the impact of Par‐4 on caspase‐8 activation in response to
TRAIL. Par‐4 was knocked‐down with siRNA in the type I cells, PC‐3 and SW480, and the
cells were then treated with TRAIL. Activation of caspase‐8 was studied by Western blot
analysis using a cleaved caspase‐8 specific antibody, and by measuring the amount of
active caspase‐8 using a fluorescent substrate. The activation of caspase‐8 that follows
TRAIL treatment was compromised when Par‐4 was knocked‐down (Fig. 2.3 A & B).
Abundant activation of caspase‐8 does not occur in type II cells, as the very low levels of
active caspase‐8 formed at the DISC is insufficient to directly activate caspase‐3.
Instead, the active caspase‐8 is adequate to trigger initiator caspase‐9, thus the cascade
proceeds via the mitochondrial amplification loop. Since apoptosis in type II cells
requires Par‐4, I examined whether activation of caspase‐8 and caspase‐9 is
compromised in the absence of Par‐4. The Par‐4 knock‐down and control H460 cells
were exposed to TRAIL and initiator caspases‐8 and ‐9 were checked for activation.
Negligible activation of caspase‐8 was observed in the Par‐4 knock‐down cells relative to
the control cells, and this low activity was inadequate to trigger the mitochondrial
amplification loop, as judged by the complete loss of caspase‐9 activation in the absence
of Par‐4 (Fig. 2.3 C).

Par‐4 regulates membrane translocation of caspase‐8 and DISC formation
I analyzed specific early events in the TRAIL signaling pathway to evaluate the
mechanism by which Par‐4 regulates activation of caspase‐8. Pro‐caspase‐8, which
normally resides in the mitochondria, is recruited to the DISC during death ligand
signaling (Qin et al., 2001). Pro‐caspase‐8 translocates to the cell membrane upon
death receptor activation, and is recruited to this receptor by FADD for formation of the
DISC, where pro‐caspase‐8 converts to active caspase‐8. Since several lines of evidence,
such as regulation of Fas trafficking by Par‐4 (Ranganathan and Rangnekar, 2005),
interactions of Par‐4 with actin (Vetterkind et al., 2005), and Par‐4 regulation of myosin
light chain phosphorylation (Vetterkind and Morgan, 2008), indicate a role for Par‐4 in
controlling intracellular protein traffic, I investigated whether Par‐4 is involved in the
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Figure 2.2 : Par‐4 is necessary for activation of caspase‐3
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Figure 2.2 : Par‐4 is necessary for activation of caspase‐3 :

Par‐4 inhibition inhibits caspase‐3 activation by TRAIL: PC‐3 cells were transfected with control,
Par‐4, or PKA siRNA, and 72hrs later treated with TRAIL for 6hrs. The cells were lysed, and
Western blot analysis was done for Par‐4, phospho Par‐4, and active caspase‐3. Actin was used
as a loading control.
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Figure 2.3 : Par‐4 is necessary for caspase‐8 activation by TRAIL
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Figure 2.3 : Par‐4 is necessary for caspase‐8 activation by TRAIL
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Figure 2.3 : Par‐4 is necessary for activation of caspase‐8 by TRAIL.

PC‐3 (A) and SW‐480 (B) cells were transfected with control or Par‐4 siRNA, and, 72hrs
later, treated with TRAIL for 1 or 3 hours (h). The cells were analyzed for caspase‐8
activation by a fluorometric caspase activation assay and western blot. The blot was
probed with antibodies specific for cleaved caspase‐8, Par‐4, and actin. The graph in the
side panel shows the results of the caspase activation assay. The results are a mean from
at least 3 independent experiments and statistical analysis was done by two way ANOVA.
Statistical significance is denoted by ** (p<0.001) or * (p<0.01).
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Figure 2.3 : Par‐4 is necessary for activation of caspase‐8 by TRAIL
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C : Capase‐8 activation in the type II cells is inhibited in the absence of Par‐4: H‐460 cells were
transfected with control or Par‐4 siRNA, and, 72hrs later, treated with TRAIL for 1 or 3 hours (h).
The cells were analyzed for Par‐4 knock‐down and caspase‐8 activation by Western blot. Actin
was used as loading control.
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Figure 2.4 : Par‐4 facilitates membrane translocation of caspase‐8 and FADD
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Figure 2.4 : Par‐4 facilitates membrane translocation of caspase‐8 and FADD

A : PC‐3 cells were transfected with control or Par‐4 siRNA for 72hrs, and subsequently
treated with TRAIL for the indicated time points. The cells were fixed, and immunostained
for caspase‐8 (shown in green) and Na+/K+ ATPase (Red). Representative confocal
microscope images are shown for each time point and co‐localization of caspase‐8 with
the marker at the membrane is indicated with arrows. The Western blot shows Par‐4
knock‐down with siRNA. The bar graph indicates the mean number of cells showing
caspase‐8 in the membrane of control and Par‐4 knock‐down cells. The results are a mean
of 3 independent experiments and statistical significance as measured by two way ANOVA
is denoted by * (p<0.001).

B : Fractionation analysis ‐ The PC‐3 cells were transfected with siRNA for Par‐4 or a non‐
specific control, and, after 72hrs, treated with TRAIL for 15mins. The membrane was
fractionated from the whole cell lysate, and analyzed by Western blot for FADD, DR‐5, Par‐
4, and caveolin‐1.
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trafficking of DISC components to the membrane. I immunostained untreated or TRAIL‐
treated cells (with or without Par‐4 knock‐down) for pro‐caspase‐8 and Na+/K+ ATPase, a
plasma membrane marker, to detect changes in caspase‐8 localization. Caspase‐8
translocated to the membrane upon TRAIL signaling only in cells with basal levels of Par‐
4, as apparent from co‐localization with the membrane marker protein, and was
reduced by about 50% at 15 minutes in the Par‐4 knock‐down cells (Fig. 2.4 A). I also
looked at trafficking of FADD and DR5 to the cell membrane by Western blot analysis of
membrane fractions. FADD recruitment to the membrane following TRAIL treatment
was blocked in the Par‐4 knock‐down cells, while no change in membrane localization of
DR5 was observed in the presence or absence of Par‐4 (Fig. 2.4 B). As Par‐4 is known to
functionally interact with several proteins, I scrutinized Par‐4 interaction with the
caspase(s) that Par‐4 regulates. Using PC‐3 cell extracts, immunoprecipitations for Par‐
4, pro‐caspase‐8, FADD, and caspase‐3 revealed Par‐4 was easily detectable with both
caspase‐8 and FADD, but not with caspase‐3 (Fig. 2.5 A), further substantiating Par‐4 as
a regulator of caspase‐8 and FADD membrane trafficking. In order to evaluate which
domain of Par‐4 was responsible for this interaction, I transfected the PC‐3 cells with
two different mutants of Par‐4, a ΔZIP‐GFP mutant and another mutant containing the
region of amino acids from 1‐204‐GFP, both of which lack the c‐terminal leucine zipper
motif, known for mediating protein‐protein interactions and performed co‐
immunoprecipitations with caspase‐8. Not surprisingly, I discovered that the leucine
zipper domain was central to the interaction of Par‐4 and caspase‐8 as the mutants
lacking the leucine zipper failed to co‐immunoprecipitate with caspase‐8 (Fig 2.5 B).

DR5 and DR4 have been reported to concentrate in the caveolin‐rich lipid raft
microdomains in the cell membrane during apoptotic signaling by TRAIL, while
activation of NF‐κB occurs from the non‐raft localized death receptors in response to
TRAIL (Song et al., 2007). Although DR5 continued to be localized to the membrane
upon Par‐4 silencing, I assessed whether Par‐4 regulates passage of DR5 into the rafts.
PC‐3 cells were treated with control or Par‐4 siRNA, exposed to TRAIL for the indicated
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Figure 2.5 : Interaction of Par‐4 with caspase‐8 and FADD

A : Par‐4 interacts with pro‐caspase‐8 and FADD in PC‐3 cells: PC‐3 cells were
immunoprecipitated with control, Par‐4, FADD, and pro‐caspase‐8 antibodies, and the
immunoprepitates were analyzed for Par‐4 by Western blot. Ten percent of the whole
cell lysate used for each immunoprecipitation was used as input control. Additionally,
in a similar experiment, the PC‐3 cells were immunoprecipitated using control, Par‐4,
caspase‐8, or caspase‐3 antibodies, and analyzed for Par‐4 by Western blot.

B : Identification of the domain of Par‐4 binding to caspase‐8: PC‐3 cells were
transfected with Par‐4‐GFP, ΔZIP‐GFP or 1‐204‐GFP for 48h and then the cell lysates
were immunoprecipitated with control, Par‐4 and pro‐caspase‐8 antibodies. The
immunoprecipitates were analyzed for Par‐4 using western blot.
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time points, and immunostained for DR5 or caspase‐8 and caveolin‐1, a marker for lipid
rafts. When cells with siRNA‐mediated knock‐down of endogenous Par‐4 were treated
with TRAIL, DR5 did not co‐localize with caveolin‐1. In contrast, in cells with control
siRNA, TRAIL treatment stimulated movement (as early as 15 mins) of DR5 into the rafts,
as seen from co‐localization of DR5 with caveolin‐1 (Fig. 2.6 A). Similarly, in the control
cells caspase‐8 was found to traffic to the caveolin‐1‐rich compartment (within 15 mins
after TRAIL treatment), but not in the Par‐4 knock‐down cells. Interestingly, the number
of cells with caspase‐8 in the lipid rafts decreased gradually with time in the cells with
basal levels of Par‐4, coincident with the activation of caspase‐8 (Fig. 2.6 B).
Stabilization of receptor aggregates following DISC formation is an essential
mechanism among death receptors to ensure complete and profuse activation of the
initiator caspase (Feig et al., 2007). The presence of endogenous Par‐4 in the control
cells allowed stabilization of the receptor aggregates for completion of the pathway, but
formation of aggregates (within 5 mins) and quick dissolution of the complex (as early as
15 mins) was observed in the Par‐4 knock‐down cells (Fig. 2.7). All these observations
together suggest a crucial role for Par‐4 in the activation of initiator caspase‐8 following
TRAIL signaling.
Discussion
In this study I have identified a unique regulatory role for Par‐4: facilitating
activation of caspase‐8 in the TRAIL apoptotic pathway. Par‐4 mobilizes caspase‐8 and
FADD to the cell membrane, and is thus involved in the TRAIL signaling pathway at a
very early stage. Since a basic, generic step such as activation of one of the most initial
caspases, caspase‐8 is regulated by Par‐4, apoptosis in both the type I and type II cells
depend on Par‐4 function.

Consequently, Par‐4 also contributes to the major

downstream molecular events associated with DISC formation, such as receptor
movement to the rafts and receptor aggregation.
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Figure 2.6 : Par‐4 regulates movement of DR5 into lipid rafts with TRAIL
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Figure 2.6 : Par‐4 regulates movement of caspase‐8 into lipid rafts
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Figure 2.6 : Par‐4 regulates trafficking of DR5 and caspase‐8 to the lipid rafts:

A : PC‐3 cells were treated with Par‐4 or control siRNA, followed by TRAIL treatment for the
indicated times. The cells were then fixed and immunostained for either DR5 (Green) along
with Caveolin‐1 (red), and visualized via confocal microscopy.

B : PC‐3 cells were treated with control or Par‐4 siRNA, followed by TRAIL treatment for the
indicated times. The cells were then fixed and immunostained for either Caspase‐8 (Green)
along with Caveolin‐1 (red), and visualized via confocal microscopy.
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Figure 2.7 : Destabilization of Death receptor aggregates in the absence of Par‐4
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Figure 2.7 : De‐stabilization of death receptor aggregates in the absence of Par‐4

PC‐3 cells were transfected with control or Par‐4 siRNA, and, after 72hrs, treated with TRAIL for
the indicated time points. The cells were then fixed, and immunocytochemistry was performed
for DR‐5 (green) and Par‐4 (red). In the representative fluorescent images shown for each time
point, receptor clusters are indicated with arrows.
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The TNF family of receptors can be classified as TNF like or CD95 like based on
whether or not NF‐κB activation is the predominant downstream event of receptor
signaling. CD95/Fas, DR4 and DR5 preferentially activate caspase‐8 subsequent to
receptor activation (Peter, 2000) and fall into the same category. Several molecular
events associated with DISC formation have been reported for Fas, as follows. As a first
step, a number of ligand bound death receptor trimers cluster together to form SDS
stable microaggregates where a low level DISC is formed by recruitment of FADD and
caspase‐8. This complex is relocated to the lipid rafts where, the receptor aggregates
form large platforms for efficient activation of a large number of caspase‐8 molecules.
The caspase‐8 that is activated by conformational change undergoes auto catalytic
cleavage and is released into the cytoplasm (Boatright et al., 2003).

Since TRAIL

receptors and Fas display similar downstream signaling, it is possible that the associated
minor molecular events are also comparable. Not surprisingly, I found formation DR5
clusters upon TRAIL signaling and a remarkable dissolution of the gathered clusters in
the absence of Par‐4. Par‐4 may, however, enable stabilization of clusters consequent
to caspase‐8 activation, as reported for Fas (Algeciras‐Schimnich et al., 2002) and not
have a direct role in aggregation.

Soluble TRAIL is a popular cancer selective apoptotic agent; however, aggregated
or antibody linked forms of TRAIL that are insoluble do cause apoptosis of certain
normal cells owing to increased receptor aggregation by these forms of TRAIL (Almasan
and Ashkenazi, 2003). The receptor Fas, on the other hand, is normally found as pre‐
associated micro aggregates. Such a discrepancy in receptor aggregation could be one
of the underlying mechanisms of cancer selective apoptotic potential of TRAIL, which is
again redolent of Par‐4, given the effect of Par‐4 on receptor aggregation in TRAIL
treated cells (Fig. 2.7).

Although I detected some similarity in the downstream molecular events of both
DR5 and Fas, TRAIL signaling, unlike FasL, selectively targets transformed cells. Par‐4 is

56

actively involved in the Fas pathway as well; however, it is not known whether Par‐4 has
additional roles in the Fas pathway besides trafficking Fas to the cell membrane. Akt, a
known inhibitor (Goswami et al., 2005) and substrate (Joshi et al., 2008) of Par‐4,
inhibits DISC assembly and caspase‐8 recruitment during Fas mediated apoptosis in
CD28 activated cells (Jones et al., 2002), pointing to a role for Par‐4 in the process.
Moreover, PI3K, the activator of Akt signaling inhibits CD95 receptor aggregation and
caspase‐8 cleavage at the DISC by modulating lateral diffusion of Fas (Varadhachary et
al., 2001), and contributing to the resistance of Th2 lymphocytes to Fas mediated
apoptosis (Varadhachary et al., 1999).

Remarkably, loss of Par‐4 favors Th2 type

differentiation over Th1, in the CD4+ T helper lymphocytes (Lafuente et al., 2003); it
would be interesting to determine whether all the effects of PI3K and Akt on the Fas
pathway are attributable to Par‐4. Nevertheless, it is tempting to speculate that Par‐4
confers cancer selective apoptotic potential to TRAIL while being an obligatory member
of the Fas pathway, at least in the cancer cells.

Par‐4 is found in complex with caspase‐8 and FADD in untreated PC‐3 cells. A
readily available complex would facilitate swift recruitment to the membrane upon
signaling. However, it is not clear whether Par‐4, FADD and caspase‐8 are present in a
single complex or discrete pools of Par‐4 are associated with FADD and caspase‐8
independently. It is also possible that the Par‐4 – caspase‐8 complex detected in the
untreated PC‐3 cells is the source of the basal level of active caspase‐8 observed in these
cells (Figure 2.3 A) and such a complex is not formed in other normal cell types and in
vivo under normal physiological conditions.

Previous studies suggest a requirement for adaptors (e.g., FADD and TRADD),
additional caspases (e.g., caspase‐2 and ‐10) (Shin et al., 2005), or kinases (e.g., RIP, CK‐
1, and CK‐2) for the activation of caspase‐8 in response to death ligands, particularly
TRAIL (Almasan and Ashkenazi, 2003; Wang et al., 2006). However, most of the work
stipulating conditions of initial caspase activation in response to death ligands such as
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TRAIL were performed in cells with ample Par‐4, and, therefore, were not predisposed
to discover a role for Par‐4 in caspase‐8 activation. Besides, very early studies of
caspase‐8 activation were done in vitro, where pro‐caspase‐8 molecules would have
been readily available for activation and not lodged in a spatially distinct compartment
(the mitochondria) that necessitates caspase‐8 transport to its site of activation. In view
of these circumstances, it is reasonable that the role of Par‐4 as a vital component of the
caspase‐8 activation complex has remained undiscovered until now. In addition to
regulating caspase‐8 activation, Par‐4 may also be required for completion of TRAIL
apoptotic signaling, as Par‐4 regulates many of inhibitors of apoptosis, such as c‐FLIP
(Gao et al., 2006), Bcl‐2, and NF‐κB (Ranganathan and Rangnekar, 2005). Certain
epithelial tumors acquire resistance to TRAIL as a result of over‐production of the
cytokine IL‐4 (Todaro et al., 2008), which is yet another target down‐regulated by Par‐4
(Lafuente et al., 2003). This implies Par‐4 may be a crucial regulator of various facets of
TRAIL signaling. Moreover, Par‐4 is inactivated by Akt1 in certain cancer cells (Goswami
et al., 2005) that are resistant to TRAIL, and Par‐4 is activated by microtubule‐ and Akt‐
inhibitors, as well as doxorubicin (Goswami et al., 2005; Gurumurthy et al., 2005), all of
which are known to sensitize resistant cancer cells to apoptosis by TRAIL (Wu et al.,
2004). Hence it is highly probable that Par‐4 is yet another novel entity that contributes
to TRAIL resistance among some tumors.

With this newly discovered Par‐4 requirement in TRAIL signaling, therapeutic
strategies can be revisited, taking into consideration that Par‐4 is frequently inactivated
by kinases and oncogenes in cancer. As Par‐4 induces apoptosis selectively in cancer
cells, specifically activating Par‐4 would be a prudent way to sensitize tumors to TRAIL,
thereby making the combination treatment a relatively non‐toxic, therapeutic option.

Copyright © Padhma Ranganathan 2008
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Chapter Three
Regulation of Par‐4 by Caspases
Introduction
Apoptosis by TRAIL involves activation of both initiator and effector caspases,
which target various death substrates to complete the apoptotic program. Effector
caspases, such as caspases ‐3, ‐6 and ‐7, are principal proteases that structurally and
functionally dismantle the cell by breaking down death substrates, which include
cytoskeletal proteins, nuclear matrix components, and other proteins essential for the
survival. Additionally, certain proteins, such as CAD (Caspase Activated DNAse), Acinus,
DEDD (an apoptosis inducer that translocates from cytoplasm to the nucleolus), that
participate actively in apoptosis, as well as kinases such as PAK (p21 Activated Kinase),
FAK (Focal Adhesion Kinase) and PKC are activated by caspases for apoptotic or non‐
apoptotic purposes (Earnshaw et al., 1999; Lee et al., 2002; Sahara et al., 1999).
Numerous substrates have been identified for effector caspases, yet the initiator
caspases, especially caspase‐8, have only a limited substrate repertoire. Among those
reported, caspase‐3, Bid, RIP (Receptor Interacting Protein), and plectin are the prime
substrates of caspase‐8 (Stegh et al., 2000). Caspase‐9, on the other hand, acts on
Gelsolin , Vimentin (Nakanishi et al., 2001), Raf‐1 (Cornelis et al., 2005) and Rb (Lemaire
et al., 2005), in addition to its proverbial substrates, the effector caspases. Thus, the
initiator caspases take on dual roles, that of an initiator by activating effector caspases
and that of an effector by acting on non‐caspase substrates.
Par‐4 is a regulator of apoptosis in that it promotes Fas trafficking to the cell
membrane, and inhibits the anti‐apoptotic NF‐κB activity. In addition, Par‐4 helps
augment the apoptotic signal via the mitochondrial amplification loop by down‐
regulating Bcl2 (Cheema et al., 2003). The functional core of Par‐4, the SAC domain
causes selective apoptosis of cancer cells and confers tumor resistance in transgenic
mice. Here Ireport that Par‐4 is actively regulated along the TRAIL pathway in two
different ways: (1) Enhanced nuclear translocation, and (2) Endogenous generation of a
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SAC‐like domain by caspase mediated cleavage. Incidentally, Par‐4 activation serves as a
molecular nexus for the extrinsic and intrinsic apoptotic pathways in that it allows
unhindered progress of cell death.

Materials and Methods
Cell lines and Reagents
Androgen independent prostate cancer cells PC‐3 were previously described (El‐
Guendy et al., 2003). Human lung cancer cells H460 were bought from ATCC and
maintained as per instructions.

TRAIL was purchased from Calbiochem.

Active

recombinant human caspase‐8 and specific caspase inhibitors were purchased from
Biovision Research Products, Ca.

Plasmid constructs, siRNA and transfection
GFP vector and Par‐4‐GFP (C terminal) constructs were described previously (El‐
Guendy et al., 2003). The D123 to 123A, D200 to 200A, D209 to 209A, S124 to 124A, and
S124 to 124D point mutants of Par‐4 were made by site directed mutagenesis, thereby
changing the sequence at D 123 and 200 from GAT to GCT (Alanine), S 124 from TCC to
GCT (Alanine) or GAC (Aspartic acid). siRNA for caspase‐8, caspase‐9 and the non‐
targeting control were from Santa Cruz Biotechnology, Inc. Cells were transiently
transfected with the indicated plasmids using lipofectamine reagent (Invitrogen Life
Technologies, CA) as per manufacturer’s instructions, and appropriately processed 24
hours later.

Antibodies and other reagents
Cells were harvested and subjected to SDS‐PAGE followed by Western blot
analysis using appropriate antibodies as described (Vasudevan et al., 2006). Rabbit
polyclonal antibody for Par‐4 (sc‐1807) was from Santa Cruz Biotechnology,Inc.
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Antibodies for cleaved caspase‐8 (9496) and caspase‐9 (9502) were from Cell Signaling,
Beverly, MA. The antibody for actin was from Sigma‐Aldrich, St. Louis, MO. HRP
conjugated secondary mouse (NA931) and rabbit (NA934) antibodies were from
Amersham/GE Healthcare, Buckinghamshire, UK.

In vitro caspase cleavage assay
GST or GST‐Par‐4 purified from E. coli were incubated with the specified units of
recombinant active caspase‐8 for 1 hour at 37°C in reaction buffer containing 50mM
Hepes pH 7.2, 50mM NaCl, 0.1% CHAPS, 10mM EDTA, 5% Glycerol and 10mM DTT. The
mix was then subjected to Western blot analysis.

Apoptosis assay and immunocytochemistry
Cells were plated in chamber slides, transfected with the indicated plasmids
(expressing GFP control or Par‐4‐GFP), treated with caspase inhibitors and TRAIL, and
formalin fixed after the indicated times.

The cells were subjected to

immunocytochemistry for Par‐4 followed by secondary antibody conjugated to Alexa
Fluor 594 (red fluorescence) from Molecular Probes, Invitrogen. Nuclei were stained
with DAPI (4, 6, diamidino‐2‐phenyl indole for cyan fluorescence) from Vector
Laboratories, Inc., Burlingame, CA. The cells were visualized via confocal, fluorescent
microscopy to examine localization and nuclear condensation as a measure of
apoptosis. A minimum of 200 cells were counted in each experiment, which was
performed at least three times (Gurumurthy et al., 2005).

Results
Caspase‐8 dependent nuclear translocation of Par‐4 by TRAIL
Par‐4 is present primarily in the cytoplasm in cancer cells under non‐apoptotic
conditions. Ectopically over‐expressed Par‐4 localizes to the nucleus and the apoptotic

61

events that ensue are particularly dependent on this localization (El‐Guendy et al.,
2003). Since Par‐4 plays an essential role in TRAIL inducible apoptosis, I asked whether
endogenous Par‐4 in PC‐3 cells would translocate to the nucleus in response to TRAIL.
Par‐4 localization changed from that of cytoplasmic to nuclear in 24h post‐TRAIL
treatment (Figure 3.1 A), and the cells were shrunken in addition to reduction in cell
numbers, indicating apoptosis. To further corroborate the change in Par‐4 localization, I
performed fractionation studies on untreated or TRAIL treated cells. Par‐4 was present
in both the cytoplasm and nucleus in untreated cells; however the nuclear levels of Par‐
4 increased within 12h of TRAIL exposure (Figure 3.1 B). Since apoptosis is not apparent
at this time point, these data provide additional evidence that Par‐4 translocation to the
nucleus precedes execution of cell death, as previously established (El‐Guendy et al.,
2003).

In order to better study the dynamics of TRAIL mediated nuclear translocation of
Par‐4, I used a competitive, irreversible, peptide inhibitor of caspase‐8. PC‐3 cells were
pre‐treated with the inhibitor, and subsequently treated with TRAIL. A significant
reduction in the number of apoptotic cells, as well as cells with nuclear Par‐4 was
observed when caspase‐8 was inhibited following TRAIL treatment, as compared to the
control with uninhibited activity of caspase‐8 (Figure 3.2 A). Representative fluorescent
microscopy images are shown in Figure 3.2 B.

Since Par‐4 plays an important role in caspase‐8 activation, it is possible that the
nuclear translocation of Par‐4 that is affiliated with caspase‐8 activity is merely a facet of
the TRAIL signaling pathway. To investigate whether, nuclear localization of Par‐4
presents an appearance of being regulated by caspase‐8 because of Par‐4’s involvement
in the TRAIL signaling pathway, or whether it is actively regulated by caspase‐8, PC‐3
cells were transfected with Par‐4, treated with either caspase‐8 or caspase‐3 inhibitors,
and 24h later, quantitatively analyzed for apoptosis.

Apoptosis of the Par‐4

transfectants strictly correlated with nuclear translocation of Par‐4; conversely, upon
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Figure 3.1 : TRAIL induces nuclear translocation of Par‐4

A

Vehicle

TRAIL

Par‐4 – Green; Nucleus ‐ Red

Cytoplasmic
fraction

B
TRAIL:

0h

12h

Par‐4
GRP78
MnSOD
Lamin

63

Nuclear
fraction
0h

12h

Figure 3.1 : TRAIL induces nuclear translocation of Par‐4

A: PC‐3 cells were treated with Vehicle or TRAIL for 24h, stained for Par‐4 (green) and the
nucleus (DAPI shown in Red) and visualized using a fluorescent microscope.

B: Cytoplasmic and nuclear fractions were isolated from TRAIL treated PC‐3 cells and
analyzed for Par‐4 localization using western blot. GRP‐78 and MnSOD were used as
cytoplasmic markers and Lamin was used as the nuclear marker.
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Figure 3.2 : TRAIL mediated nuclear import of Par‐4 is caspase‐8 dependent
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Figure 3.2 : TRAIL mediated nuclear import of Par‐4 is caspase‐8 dependent

A: PC‐3 cells were treated with caspase‐8 inhibitor for 6h, followed by treatment with
vehicle or TRAIL for 12h and analyzed for apoptosis (measured by nuclear
condensation using DAPI) and co‐related with the number of cells with nuclear Par‐4.

B: Representative pictures of TRAIL treated cells, with or without caspase‐8 inhibitor.
The nuclear DAPI staining is shown in red and immunostaining for Par‐4 is shown in
green.
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inhibition of caspase‐8 activity, both nuclear localization and apoptosis by Par‐4 were
attenuated. Inhibition of caspase‐3 activity, however, allowed copious nuclear entry of
Par‐4 although apoptosis was blocked (Figure 3.3) indicating that nuclear import of Par‐
4 is an episode dynamically regulated by caspase‐8 that precedes cell death.

Akt‐1 is the major regulator of the nuclear – cytoplasmic shuttling of Par‐4 in the
cancer cells. Akt‐1 mediated phosphorylation of Par‐4 generates a binding site for the
adaptor protein 14‐3‐3 θ, which interacts with and sequesters Par‐4 in the cytoplasm by
way of promoting cell survival (Goswami et al., 2005). Since caspase‐8 regulates the
nuclear translocation of Par‐4, I decided to test the involvement of Akt‐1 in this process.
To examine whether Akt‐1 is a direct substrate of caspase‐8, PC‐3 cells were treated
with TRAIL for various time points (up to 24h), and analyzed for possible Akt‐1 cleavage.
TRAIL treatment did not alter Akt‐1 levels significantly (Figure 3.4 A) although the minor
reduction in protein amounts observed may be attributed to cell death and cleavage of
Akt‐1 by caspase‐3 (Jahani‐Asl et al., 2007).

I next examined the effect of TRAIL on 14‐3‐3 θ, as this particular protein has
previously been reported to be an apoptotic target of many caspases, including caspase‐
8 (Nomura et al., 2003). A considerable decrease in protein amounts of 14‐3‐3 θ was
noticed as early as 1h after TRAIL treatment, and at 12h, the protein was almost
completely broken down signifying involvement in caspase‐8 dependent release of Par‐4
into the nucleus (Figure 3.4 B). The cells used in this study are cancer cells, which have
high levels of PKA activity and therefore, an active form of Par‐4; the only other
requirement is for Par‐4 to be translocated into the nucleus which is fulfilled by caspase‐
8 through 14‐3‐3 θ cleavage, thus promoting amplification of the TRAIL apoptotic signal.

Identification of Par‐4 as a novel substrate of Caspases
In addition to the mutual regulation of Par‐4 nuclear translocation by caspase‐8
and transport of pro‐caspase‐8 to the plasma membrane by Par‐4 (Chapter 2),
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Figure 3.3 : Nuclear Import of Par‐4 depends on caspase‐8 activity

Figure 3.3: Nuclear import of Par‐4 depends on caspase‐8 activity
PC‐3 cells were transfected with GFP‐Par‐4 and treated with caspase‐8 or caspase‐3
inhibitors for 24h. The cells were then fixed and apoptosis was analyzed using nuclear
condensation as measured by DAPI and co‐related with nuclear Par‐4.
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Figure 3.4 : Cleavage of 14‐3‐3 θ in response to TRAIL allows nuclear
translocation of Par‐4
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Figure 3.4 : Cleavage of 14‐3‐3 in response to TRAIL allows nuclear transport of Par‐
4
A: Lysates of PC‐3 cells treated with TRAIL for the indicated time points were
analyzed for Akt expression levels by western blot. Actin was used as a loading
control
B: TRAIL treated PC‐3 cell lysates were analyzed by western blot for expression levels
of the adapter protein 14‐3‐3θ.
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additional outcomes of the interaction of Par‐4 with pro‐caspase‐8 (Chapter 2, Figure
2.5) are possible as well. As it is not clear whether Par‐4 dissociates from caspase‐8
following membrane translocation of the inactive zymogen, I examined the possibility
that Par‐4 could still be associated with the caspase following activation.

Close

association with an active protease implies an enzyme—substrate relationship and I
inquired whether that was the case with caspase‐8 and Par‐4. Caspases choose their
substrates based on consensus recognition and cleavage sequences; careful inspection
of the Par‐4 protein sequence revealed the presence of four putative caspase consensus
sites (sequences specified in Table 3.1) at aspartic acid residues 123, 200, 209 and 287
(Figure 3.5). Cleavage of Par‐4 at each of these sites would generate fragments of
various sizes as described in Table 3.2. However, given that aspartic acids 200 and 209
are in close proximity, differences in fragment sizes will not be apparent if either or even
both of the sites are utilized.

With this information in hand, I asked whether Par‐4 was, in fact, a direct
substrate of caspase‐8 in vitro using recombinant caspase‐8 and GST‐Par‐4. GST‐Par‐4
was incubated with the indicated amounts of recombinant caspase‐8, and the integrity
of Par‐4 protein was analyzed by Western blot. Two major fragments of approximate
sizes 25kd and 15kd, and a minor one of roughly 20kd were cleaved off from GST‐Par‐4
when incubated with caspase‐8 (Figure 3.6 A). Based on the computed fragment sizes
(Table 3.1), the three fragments might represent cleavage at the three residues 123, 200
/ 209, and 287. In order to verify that Par‐4 cleavage by caspase‐8 is an authentic
process that takes place in the cells, I activated endogenous caspase‐8 in the PC‐3 cells
with TRAIL and examined the effect on Par‐4 24h later. Two fragments of Par‐4, similar
to those produced by recombinant caspase‐8 in vitro were generated with TRAIL
treatment (Figure 3.6 B), pointing towards a role for TRAIL signaling in Par‐4 break
down.
So as to ascertain the role of caspase‐8 in the cleavage of Par‐4 in vivo along the
TRAIL pathway, I pre‐treated the PC‐3 cells with caspase‐8 and caspase‐3 inhibitors and
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Figure 3.5 : Caspase-8 consensus sites in Par-4
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Figure 3.5 : Caspase consensus sites in Par‐4:

Four different caspase‐8 cleavage consensus sequences were found in Par‐4, at
aspartic acid residues 123, 200, 209 and 287. Cleavage of Par‐4 at each of these
sites will result in fragments of the indicated sizes. Among these, the 9kd fragment
is of interest because it contains the functional core of Par‐4.
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Table 3.1 : Putative caspase consensus sequences in Par-4

Aspartate
residue
(Rat, Human)

Rat Sequence

Human
Sequence

123, 134

EEP D

EEP D

200, 211

SLP D

NLL D

209, 220

LPQ D

LLQ D

287, 298

LMQ D

LMQ D

Table 3.1 : Caspase consensus sequence in human and rat Par‐4.

The caspase consensus sites in rat and human Par‐4 and the corresponding
consensus sequence.
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Table 3.2 : Possible Caspase cleavage fragments in Par-4

Fragment

Size

Domains

Full length

38 KD

SAC, LZ

1‐287

33 KD

SAC

124 – 332

24 KD

SAC, LZ

1 – 200

23 KD

SAC

124 ‐ 287

19 KD

SAC

201 – 332

15 KD

LZ

1 – 123

14 KD

‐‐

201 ‐ 287

10 KD

‐‐

124 – 200

9 KD

SAC

288 ‐ 332

5 KD

LZ

Table 3.2 : Caspase cleavage sites and fragments in Par‐4.

A complete list of the various possible caspase cleavage products of Par‐4 with
their respective sizes and the major functional domains is given. The fragment
length and sizes are indicated for rat Par‐4; the molecular weight of human Par‐4
fragments would be approximately 2kd higher.
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Figure 3.6 : Par‐4 is a substrate of caspase‐8 in vitro and in vivo
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Figure 3.6 : Par‐4 is a substrate of caspase‐8 in vitro and in vivo

A: In vitro cleavage of Par‐4 by caspase‐8 ‐ 1μg of GST‐Par‐4 was incubated with the
indicated amounts of recombinant caspase‐8 for 1h at 37°C and analyzed for Par‐4
cleavage by western blot.

B: PC‐3 cells were left untreated or treated with TRAIL for 24h and analyzed by
western blot.
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followed up with TRAIL.

Subsequent to TRAIL treatment, an N terminal cleavage

producing a 14kd fragment presumably containing the region from 1‐123, susceptible to
inhibition by caspase‐8 but not caspase‐3 inhibitor, was observed (Figure 3. 7). The
23kd product was present constitutively in all the samples, suggesting this cleavage was
not mediated by caspase‐8, which is activated specifically in response to TRAIL.
Although caspases are expected to maintain stringent criteria with regard to consensus
sequence recognition, instances of promiscuous activity are not unheard of. Hence, I
considered other caspases that might be responsible for generation of the 23kd
fragment.

The mitochondrial apoptotic pathway is involved in spontaneous apoptosis of
cells due to ‘culture shock’ and induces a basal level of caspase‐9 activity in certain cells
(Bailly‐Maitre et al., 2002; Pennati et al., 2004). Since about 10% of PC‐3 cells undergo
spontaneous apoptosis in culture, these cells may tolerate low levels of caspase‐9
activity. Moreover, these cells exhibit a Type I response to TRAIL, and as a result,
caspase‐9 activity is not enhanced beyond the basal level even upon treatment; this
may account for the constitutive, unaltered presence of the 23kd fragment in these
cells. In order to test this possibility, I used a siRNA approach on the H460 cells, which
suffer a Type II response to TRAIL. I used siRNA to knock‐down caspases ‐8 and ‐9 from
these cells which was verified by western blot. The cells were then treated with TRAIL
for the indicated time frames and analyzed for Par‐4 cleavage by western blot. TRAIL
treatment of the control cells resulted in generation of the two distinct 23kd and 14kd
fragments of Par‐4. As expected, knock‐down of caspase‐8 led to inhibition of the N‐
terminal cleavage but, did not affect the 23kd cleavage product. Caspase‐9 knock‐
down, on the other hand, inhibited generation of the 23kd fragment, indicating a
specific role for the two different caspases in Par‐4 break down (Figure 3.8).
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Figure 3. 7 :Par‐4 cleavage by caspase‐8 in response to TRAIL
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Figure 3. 7 : Par‐4 cleavage by caspase‐8 in response to TRAIL
PC‐3 cells were treated with vehicle, caspase‐8 inhibitor (IETD) or caspase‐3 inhibitor
(DEVD) for 6h followed by TRAIL for 24h. The cell lysates were then analyzed by
western blot for Par‐4 cleavage.
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Figure 3.8 : Collaboration of Caspases ‐8 and ‐9 to generate Par‐4
functional fragment
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Figure 3.8 : Collaboration of Caspases ‐8 and ‐9 to generate Par‐4 functional
fragment

H460 cells were transfected with siRNA for Caspase‐8, Caspase‐9 or non‐specific
controls for 48h. The cells were then treated with TRAIL for 3h or 6h or left
untreated and the lysates were examined on a western blot for cleavage of Par‐4.
Knockdown of Caspases ‐8 and ‐9 were checked by western and Actin was used as
the loading control.
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Delineation of the sites of caspase cleavage in Par‐4
Having clarified that Par‐4 is unmistakably cleaved into at least two fragments by
caspases ‐8 and ‐9 in response to TRAIL (and possibly other apoptotic stimuli), our next
aim was to define the actual sites in Par‐4 responsible for the generation of these
fragments. According to the putative caspase site estimate (Table 3.1), I determined
that residues 123 and 200/209 were the ones most likely to generate fragments of sizes
24/23 kd and 15/14 kd. Point mutations in GFP‐Par‐4 cDNA were made so as to change
each of these residues from aspartic acid to alanine and following transfection of PC‐3
and H460 cells with the mutants, GFP‐Par‐4/D123A, GFP‐Par‐4/D200A and GFP‐Par‐
4/D209A, I analyzed them for cleavage. The D123A mutant failed to generate the 14 kd
fragment in both PC‐3 and H460 cells, whereas the 24/23 kd product was intact (Figure
3.9 A, B). All the fragments observed in wild type Par‐4 were also obtained from the
D209A mutant, indicating this was not a genuine site (Figure 3.9 A). On the contrary,
when the Type II H460 cells were transfected with the mutants, then treated with
TRAIL, the 23kd fragment was absent from the D200A transfectants, in addition to a
decreased amount of the 14kd product (Figure 3.9 B). Interestingly, the D200A mutant
despite an intact aspartic acid at 123, yielded only to an inefficient cleavage at this site,
giving rise to a weak 14kd fragment. It is evident from these data that caspase‐8 cleaves
Par‐4 at amino acid 123 in the N terminus, generating a 14kd fragment containing the
region from 1‐123, while caspase‐9, responsible for the 23kd fragment cleaves at
residue 200 to produce the fragment comprised of amino acids 1‐200.
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Figure 3.9 : Caspases cleave Par‐4 at Aspartate residues 123 and 200
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Figure 3.9 : Caspases cleaves Par‐4 at aspartate 123 and 200

A: PC‐3 cells were transfected with GFP‐Par‐4 or GFP‐Par‐4/D123A for 24h and the cell
lysates were analyzed by western blot using Par‐4 antibody. In a similar experiment,
H460 cells were transfected with GFP‐Par‐4 and GFP‐Par‐4/D209A and analyzed by
western blot.

B: H460 cells were transfected with GFP‐Par‐4, GFP‐Par4/D123A or GFP‐Par‐4/D200A
mutants for 24h and the cell lysates were analyzed by western blot using Par‐4
antibody.
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Regulation of cleavage by phosphorylation
A casual glance at the Par‐4 protein sequence reveals the presence of a Casein
Kinase‐2 (CK‐2) phosphorylation site immediately after the caspase‐8 consensus at
residue 124 (Figure 3.10 A). Since CK‐2 is known to play a role in regulating TRAIL
inducible apoptosis (Ravi and Bedi, 2002), I were interested in finding out whether this
site would regulate cleavage of Par‐4 as well. To this end, an unphosphorylatable
mutant, GFP‐Par‐4/S124A and a phospho‐mimetic mutant GFP‐Par‐4/S124D were tested
for caspase‐8 based cleavage in the PC‐3 cells. The S124A mutant was subject to
cleavage even by the basal activity of caspase‐8 present in the untreated PC‐3 cells,
whereas the phospho‐mimetic mutant S124D was not cleaved in spite of higher
caspase‐8 activity upon TRAIL signaling (Figure 3.10 B). This suggests CK‐2 may regulate
access of caspase‐8 to the site at 123 as CK‐2 site phospho‐mimetic form of Par‐4 is not
cleaved while unphosphorylated molecules of Par‐4 are a subject of cleavage.

Generation of the functional core of Par‐4 by cleavage
Given that every cellular activity serves a purpose, I examined the functional
significance of Par‐4 cleavage at the two sites 123 and 200. It is apparent from the Par‐4
sequence that cleavage at both these sites will generate the fragment 124‐199 that
effectively contains the functional core of Par‐4 (Figure 3.11 A), the SAC domain and I
examined whether such cleavage indeed occurs. The H460 cells were chosen because
they are Type II and would stimulate profuse activation of caspase‐9, as well as caspase‐
8. I observed the appearance of the 14kd fragment as early as 3 hours following TRAIL
treatment and increase in the 23kd cleavage product starting at 6 hours.

A 9kd

fragment of Par‐4 was observed at 24 hours, suggesting sufficient cleavage at both 123
and 200 ultimately results in accumulation of the possible SAC fragment (Figure 3.11 B).
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Figure 3.10 : Cleavage of Par‐4 by caspase 8 is determined by
phosphorylation
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Figure 3.10 : Cleavage of Par‐4 by caspase‐8 is determined by phosphorylation

A: The N‐terminal caspase‐8 consensus is followed by a Casein kinase‐2
phosphorylation site as shown in the schematic; this phosphorylation likely regulates
substrate specificity for caspase‐8.

B: PC‐3 cells were transfected with GFP‐Par‐4, GFP‐Par‐4/124A or GFP‐Par‐4/124D
for 24h and analyzed by western blot using Par‐4 antibody for cleaved fragments of
Par‐4.
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Figure 3.11 : Possible generation of the functional core fragment, SAC, of
Par‐4 by caspases
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Figure 3.11 : Possible generation of the functional core of Par‐4 by caspases

A : Schematic of Par‐4 primary structure with representations of caspase cleavage
sites and resulting fragment sizes.

B: H460 cells were treated with TRAIL for the indicated time points and analyzed for
Par‐4 cleavage by western blot.
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Discussion
TRAIL is a widely recognized cancer selective killer agent and extensive research
is underway to examine the pathways and mechanisms operating downstream of this
cytokine. I have demonstrated here that Par‐4, another protein that causes cancer
selective apoptosis upon over expression, is actively regulated along the TRAIL pathway.
TRAIL signaling increases nuclear import of Par‐4 and results in cleavage of Par‐4 into its
active form, both regulated chiefly by caspase‐8.

Par‐4 translocation to the nucleus is increased with TRAIL signaling in
aproximately 12 hours following treatment. The structural organization of the cell and
nucleus is destroyed as a result of the breakdown of cytoskeletal proteins such as actin,
fodrin and gelsolin, and the nuclear matrix protein lamin (Philchenkov et al., 2004). As a
result of this breakdown, the nuclear/cytoplasmic barrier may be disrupted in a caspase
dependent manner leading to passive diffusion of proteins into the nucleus. However,
in the case of Par‐4, increase in nuclear amounts is seen earlier than lamin B break down
(Figure 3.1 B). Additionally, inhibition of caspase‐3 activity, which is responsible for
lamin B cleavage, does not affect Par‐4 translocation suggesting Par‐4 is being actively
transported to the nucleus in response to TRAIL. The kinase Akt is known to be an
important arbitrator of TRAIL sensitivity (Chen et al., 2001) and here, cleavage of 14‐3‐3
θ, an Akt signaling intermediate, by caspase‐8 was found to be highly co‐relative to the
increase in Par‐4 nuclear import suggesting Par‐4 might be a key component of Akt
mediated TRAIL resistance in various cell types.

Par‐4 is identified as a novel substrate of caspases that undergoes cleavage
during apoptosis. In addition I identified four putative consensus caspase sequences in
Par‐4 and verified two to be genuine sites responding to caspases ‐8 and ‐9. Although in
vivo the N terminal site alone is subject to cleavage by caspase‐8, in vitro, more than
one site was recognized and cleaved by caspase‐8, forming 3 fragments of sizes 23, 19,
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and 14 KD. This may be due to the fact that caspases display promiscuous, overlapping
activity in the presence of non limiting concentrations of substrate. The residue 287 is a
genuine caspase‐8 consensus (LXXD) and is most likely cleaved by caspase‐8 under
conditions that are similar to those that support cleavage at the N terminus. The amino
acids from 287 until 332 (the end of the protein) include the leucine zipper, which
mediates most of the protein‐protein interactions of Par‐4, including that with caspase‐
8. Cleavage at this site would confer enormous advantage to an apoptotic cell because
Par‐4 can be relieved from certain inactivating and non‐apoptotic interactions such as
with Akt‐1 and Topoisomerase‐1. I did not, however, study this site because our
primary interest was in the doubly efficient, functional core of Par‐4, the SAC domain.
Moreover, cells that are resistant to the over expression of full length Par‐4 are sensitive
to mutants that are deleted for most of the C terminal amino acids i.e. SAC and 1‐204
(El‐Guendy et al., 2003). Since cleavage at 287 would effectively eliminate only the
leucine zipper, I did not pursue this further.

Caspases are primarily involved in dismantling the cell during apoptosis,
although certain caspase targets are known to be activated by cleavage. Here, the
cleavage of Par‐4 by caspases ‐8 and ‐9 should be considered as activating since a Par‐4
molecule that has undergone cleavage by both caspases would essentially become SAC
(124‐199). The SAC domain has been demonstrated in various cell culture (El‐Guendy et
al., 2003) and animal (Zhao et al., 2007) models to efficiently cause apoptosis and cancer
resistance. The SAC domain, once produced, provides the cell with an additional thrust
into the apoptotic pathway, as it is capable of inhibiting pro‐survival NF‐κB activity (El‐
Guendy et al., 2003). Generation of SAC can be considered as the point of no return for
a cell en route apoptosis; therefore, it is not surprising that two different caspases from
distinct apoptotic pathways collaborate to produce this fragment. Isolated activation of
either caspase will not generate SAC and this probably acts as a failsafe mechanism to
guard the cells against unwarranted apoptosis. Although caspase ‐8 and ‐9 share
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substrates such as effector caspase‐3, there are no known instances of co‐operation
between the two as that reported here with Par‐4.

Another interesting issue regarding the generation of the 124‐199 fragment by
the two caspases is the sequence of events. In the Type II H460 cells, caspase‐9 is not
active to begin with; activation of caspase‐8 leads to caspase‐9 activation via Bid
cleavage and mitochondrial cytochrome c release. Therefore in these cells, Par‐4 may
not be cleaved at residue 200 prior to being cleaved at 123. In the Type I PC‐3 cells, in
contrast, caspase‐9 is not activated in response to TRAIL, yet Par‐4 is cleaved at residue
200 by the basal activity of caspase‐9 and low amounts of the 23kd fragment, which
does not increase with TRAIL, are observed. This 23kd fragment, however, cannot
become a substrate of caspase‐8, as it lacks the leucine zipper domain that is
responsible for Par‐4 – caspase‐8 interaction. This again, could be a safeguard to
protect the cells against apoptosis in response to minor stress that might activate
caspase‐9. Despite the stipulation that 123 and 200 be cleaved in that sequence in
order to generate 124‐199, the 23kd fragment occasionally appears to be accumulating
when cleavage at 123 is inhibited. This could simply be a function of the stoichiometric
availability of Par‐4 protein under conditions of caspase‐8 deficiency rather than the
product of caspase‐9 becoming a substrate of caspase‐8.

In essence, Par‐4 is regulated along the TRAIL pathway, both by being
transported into the nucleus and by caspase mediated cleavage to endow the cells with
uninhibited apoptotic activity.

Copyright © Padhma Ranganathan 2008
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Chapter Four
Summary and Future Directions
Par‐4 is a unique pro‐apoptotic, tumor suppressor known for causing selective
apoptosis of cancer cells and, in this study, I report a novel role for endogenous Par‐4 in
the extrinsic apoptotic pathway induced by TRAIL.

Par‐4 is present both in the

cytoplasm and nucleus in cancer cells and its function is tightly regulated by localization.
Moreover, Par‐4 has a modular structure – function relationship, with discrete domains
contributing to distinct functions. Although many key discoveries have been made
concerning Par‐4, the majority of the data was obtained from ectopic over‐expression
systems. Hence, this work sought to establish the role of endogenous Par‐4 in apoptosis
and identified that Par‐4 is an essential component of the TRAIL induced extrinsic
pathway besides being cleaved by caspase‐8 and translocated to the nucleus.

Par‐4 is intimately involved in trafficking caspase‐8 to the cell membrane upon
death receptor signaling, facilitating caspase‐8 activation, as a result. I also discovered
that a greater part of the succession of molecular events in the aftermath of TRAIL –
receptor engagement, such as receptor aggregation, formation of the DISC in the lipid
rafts, activation of caspase‐8 and consequent activation of downstream initiator and
effector caspases, are contingent upon Par‐4 activity. These discoveries reveal a critical
function for Par‐4 in death receptor signaling. Likewise, in a parallel installment, Par‐4 is
also regulated by caspases creating a functional regulatory loop. Accordingly, Par‐4 is
transported into the nucleus by caspase‐8 activity in addition to being cleaved, at more
than one site by the concerted action of caspases ‐8 and ‐9. Cleavage of Par‐4 at sites
123 and 200 would result in the fragment 124‐199, which includes the SAC domain.
These observations support the hypothesis that the extrinsic and intrinsic cell death
pathways collaborate in an effort to generate the apoptotic functional core of Par‐4
(Figure 4.1).
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Figure 4.1 : A model for mutual regulation of Par‐4 and caspase‐8 in the
TRAIL pathway

TRAIL
DR4/5
FADD
Pro-Casp-8
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94
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Figure

4.1

:

Mutual

regulation

of

Par‐4

and

caspase‐8:

Par‐4 mediates membrane transport and activation of pro‐caspase‐8 following
TRAIL signaling. The activated caspase‐8 then mediates nuclear translocation of Par‐
4 by breaking down 14‐3‐3. Caspase ‐8 and ‐9 in collaboration also generate a SAC
containing fragment of Par‐4; full length and cleaved Par‐4 both inhibit NF‐ΚB. All
these events consequently lead to apoptosis of the cell.
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Biological systems abound with instances of feedback regulation, where the
effects of a pathway are tempered by regulation of the regulator. Par‐4, similarly, is
required for activation of caspase‐8, following which, Par‐4 is itself cleaved by the
protease. Although both these events are interconnected, whether they are mutually
relevant functionally is an issue for deliberation. Par‐4 plays an important role in
conveying caspase‐8 to the actively forming DISC in the membrane. This event must
occur with full length Par‐4 (i.e. prior to being cleaved by caspase‐8) because, first of all,
Par‐4 binds to caspase‐8 with its leucine zipper (Figure 2.5) and evidently cleavage at
either residue 200 or 287 would render Par‐4 incompetent in this regard. Moreover,
only the pro form of a caspase would be recruited to the DISC, thus a Par‐4 molecule
that interacts with the protease zymogen at this stage cannot be subjected to any
proteolytic activity. In addition, even the basal caspase‐8 activity present in the cell is
diminished with Par‐4 siRNA (Figure 2.3 A) indicating caspase‐8 cannot act on Par‐4 or
any other substrate unless its activation is first aided by Par‐4.

Although these

observations suggest activation of caspase‐8 by Par‐4 precedes Par‐4 cleavage by
caspase‐8, it does not entirely preclude the possibility that two functionally distinct
pools of Par‐4 regulate, and are being regulated by caspase‐8 concurrently in a cell.
The cycle of Par‐4 first activating caspase‐8 before being cleaved itself points
towards a feedback regulatory loop. The caspase‐8 cleavage site in Par‐4 is the N
terminal Aspartic acid at 123. In the absence of further cleavage, the resulting fragment
of Par‐4 would be 124‐332. A mutant of Par‐4 that is deleted for the N terminal 25
amino acids displays stronger apoptotic ability than full length Par‐4, suggesting the
presence of an N terminal inhibitory domain (El‐Guendy, 2002).
Par‐4 interacts with itself to form oligomers of varying molecular masses. Based
on Par‐4 interaction with caspase‐8, and the fact that over expression of Par‐4 triggers
death via a caspase‐8 mediated pathway, it is possible that the oligomers of Par‐4 form
a platform onto which caspase‐8 molecules are brought into close proximity for auto
catalytic activation; a similar, FADD independent, phenomenon has been noted during
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ER stress mediated activation of caspase‐8 (Breckenridge et al., 2002; Ng et al., 1997).
The homo‐oligomerization of Par‐4 may amplify caspase‐8 activation in the absence of
DISC components and this process would be more efficient in the absence of the N
terminal amino acids (Gao et al., 2006), providing one more rationale for cleavage. As
this pathway reaches a threshold in the Type II cells where caspase‐9 is activated, the
cells are presumed to have reached a point of no return. The dying cell can now afford
to have Par‐4 cleaved in the middle of the caspase‐8 activating fragment (124‐332) to
generate 124‐199, as amplification of the death signal along the extrinsic axis may no
longer be required. Incidentally, the N terminal 36 amino acids of Par‐4 have an
inhibitory effect on the synthesis of c‐FLIP, an inhibitor of caspase‐8 activation (Gao et
al., 2006). This could be another positive feedback mechanism to ensure prompt and
profuse activation of caspase‐8 upon reception of apoptotic signal. Additionally, Par‐4 is
translocated to the nucleus during TRAIL signaling, presumably to inhibit the cell survival
NF‐κB pathway, and offer reinforcement to the apoptotic pathway in progress.

TRAIL, similar to Par‐4, is a cytokine implicated in the phenomenon of cancer
selective apoptosis and therefore, it is not wholly unexpected that Par‐4 is a chief
downstream component in the pathway. However, Par‐4 is not implicated in all of the
physiological functions of TRAIL. For instance, TRAIL is involved in activation induced
proliferation of T and B cells (Chou et al., 2001), whereas the Par‐4 knockout mice
display accelerated development of these lymphocytes upon activation (Lafuente et al.,
2003), indicating opposing functions under the circumstance. On the other hand, most
apoptotic functions of TRAIL are perhaps mediated by Par‐4. Par‐4 is intimately involved
in neuronal cell death in certain neurodegenerative diseases and not surprisingly, TRAIL
expression in the neurons is scanty under normal conditions. Moreover, TRAIL induces
apoptosis in the granulosa cells of the atretic follicles in the ovary (Inoue et al., 2003),
where evidently, Par‐4 expression is also elevated (Boghaert et al., 1997). Par‐4 might,
therefore, prove to be a generic regulator of caspase‐8 activation downstream of TRAIL.
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The reciprocal regulation of Par‐4 and caspase‐8 in response to TRAIL reveals a
complex relationship between two apoptotic proteins and opens up numerous
questions. First of all, although I know that Par‐4 causes membrane translocation of
caspase‐8, the specifics of this trafficking are not clearly understood. Further studies
should be undertaken to examine the regulation of membrane trafficking of caspase‐8
by Par‐4. For instance, Par‐4 has an N‐myristoylation consensus at the N terminus;
whether Par‐4 is in fact myristoylated and whether such modification has implications
on caspase‐8 trafficking and propagation of the TRAIL apoptotic signal are valid
questions that can be addressed. Numerous proteins, such as Src, Yes and Akt are
myristoylated to enable association with the membrane and cytoskeleton (Cross et al.,
1984).

Interestingly, activity of N‐myristoyltransferase, the enzyme responsible of

myristoylating proteins, is elevated in several human cancers (Magnuson et al., 1995;
Rajala et al., 2000; Selvakumar et al., 2007).

This may be a specific mechanism

contributing to the cancer selective utilization of Par‐4 by TRAIL for caspase‐8
recruitment. Secondly, as phosphorylation of Par‐4 at threonine 155 appears to be a
necessary event for TRAIL induced apoptosis, the role of this phosphorylation with
regard to caspase‐8 interaction and traffic, as well as DISC formation can be investigated
further. Par‐4 is an obligatory component of caspase‐8 activation in response to TRAIL
in our experimental system. However, I do not know whether activation of caspase‐8
under all conditions entails Par‐4 mediated membrane translocation. In order to answer
this question, the requirement of Par‐4 for this process has to be tested in response to
various other death receptor ligands such as TNF‐α and FasL and in other experimental
models such as TCR/BCR activation. The Par‐4 knockout does not phenocopy the
caspase‐8 knockout indicating that Par‐4 may be expendable in the extrinsic apoptotic
pathway during embryogenesis and perhaps, across cell types.

Caspase‐8 interacts with the leucine zipper of Par‐4. The domain of caspase‐8
that is responsible for this interaction, however, is not known. Caspase‐8 binds to FADD
with its DED (Death Effector Domain), which mediates protein – protein interactions,
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precluding the involvement of this region in its interaction with Par‐4. Yet, it is possible
that Par‐4 interacts with the DED motif during trafficking, prior to caspase‐8 being
tethered to FADD. Hence, the domain of caspase‐8 responsible for its interaction with
Par‐4 would be an interesting line of inquiry. Subsequently, if the interactions of Par‐4
and FADD with caspase‐8 turn out to be mutually exclusive, it would be interesting to
study how Par‐4 is brought in to the vicinity of the DISC and activated caspase‐8 for
subsequent cleavage.

Par‐4 interacts with itself to form dimers, tetramers, and octamers (Gao et al.,
2006); such oligomerization can have an impact on the interaction of Par‐4 with
caspase‐8. I do not know whether caspase‐8 can bind to all forms of Par‐4, or whether
the multimeric state of Par‐4 determines the strength of caspase‐8 interaction. In
addition, cleavage of Par‐4 at aspartate 287 should diminish Par‐4 self association and
this might have an effect on Par‐4 feeding back onto caspase‐8 amplification. Future
studies are necessary to investigate whether oligomerization of Par‐4 can influence
interaction with and cleavage by caspase‐8.

Comprehensive studies are required in order to determine the relevance of Par‐4
cleavage to the overall cell death program.

First of all, the impact of any post‐

translational modification, such as phosphorylation, that can limit caspase access to the
site at 287 should be examined.

Subsequent studies could examine the role of

prevailing conditions, such as cell type and apoptotic vs. anti apoptotic signal ratio in
determining, via such post‐translational modification, whether or not cleavage feeds
back onto the caspase cascade to complete the apoptotic program.

Cleavage of Par‐4 generates at least 3 functionally distinct fragments, the N
terminal fragment, central fragment and C terminal region. Among these, the first to be
cleaved and the most prominent is the N–terminal 14 KD fragment. Although some
observations suggest this region has an inhibitory function and would act as a dominant
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negative in isolation, further studies are required to clarify the function of this cleavage
product.

In general, although existing data point towards amplification of Par‐4

apoptotic potential by the cleavage events, further studies with a mutant deficient in
cleavable residues at both positions 123 and 200 (123‐200 AA) are necessary to verify
the contribution of cleavage to cell death by Par‐4. Along the same lines, the smallest
fragment of 9KD has to be verified as SAC containing before concluding that cleavage of
Par‐4, indeed, contributes to apoptosis.

In essence, this study identified the role of cancer selective apoptotic protein
Par‐4, in the TRAIL – caspase‐8 apoptotic axis and uncovered an essential function for
Par‐4 in the activation of caspase‐8 via regulating translocation of pro‐caspase‐8 to the
membrane. In turn, Par‐4 is conveyed to the nucleus in addition to being cleaved by the
activated caspases, completing an entire regulatory loop.

Copyright © Padhma Ranganathan 2008
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Appendix
LIST OF ABBREVIATIONS
AATF: Apoptosis‐Antagonizing Transcription Factor
AD: Alzheimer.s disease.
ALS: Amyotrophic lateral sclerosis.
APAF‐1: Apoptotic Protease Activating Factor‐1
ARC: Apoptosis Repressor with CARD
βAPP: Beta amyloid precursor protein.
BAR: Bifunctional Apoptosis Regulator
cAMP:cyclic adenosine monophosphate
CD95: Cluster of Differentiation 95
cFLIP: FLICE inhibitory protein.
cFLIPS : FLICE inhibitory protein, short form
cFLIPL : FLICE inhibitory protein, long form
CKII: Casein kinase II.
DAP kinase: death associated protein kinase.
DAPI: 4’,6’‐diamidino‐2‐phenylindole hydrochloride.
DISC: Death Inducing Signaling Complex.
Dlk: DAP‐like kinase
DMEM: Dulbeco’s modified Eagle medium.
DTT: Dithiothreitol.
ERK: Extracellular Signal‐Regulated kinase.
FADD: Fas associated death domain protein.
FasL: Fas ligand.
FBS: Fetal bovine serum.
FLICE: FADD like ICE (caspase 8).
GFP: Green fluorescence protein.
HEL: Human embryonic lung fibroblast
HEPES: N‐2‐hydroxyethylpiperazine N’‐2‐ethanesulfonic acid.
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IAPs: Inhibitor of Apoptosis Proteins.
ICC: immunocytochemistry
IGF: Insulin growth factor.
IFNγ: Interferon γ
IκB: inhibitor of κB.
IL‐2: Interleukin‐2
Jnk: c‐Jun N‐terminal kinase
kD: kilodalton
MEF: Mouse Embryonic Fibroblasts
NES: Nuclear exclusion sequence.
NGF: Neuronal growth factor
NF‐κB: Nuclear factor‐κB
NHBE: Normal bronchial epithelial cells
NLS: Nuclear localization sequence.
NSCLC : Non Small Cell Lung Carcinoma
PAK: p21 Activated Kinase
Par‐4: Prostate apoptosis response 4.
PBS: phosphate buffered saline
PKA: Protein kinase A.
PKC: Protein kinase C.
PML: Promyelocytic leukemia.
Rb: Retinoblastoma
RCC: Renal cell carcinomas.
RIPA: Radio Immuno Precipitation Assay
SAC: Selective Apoptosis‐induction in Cancer cells
SCLC : Small cell lung carcinoma
SDS: Sodium dodecylsulfate.
SDS‐PAGE: Sodium dodecylsulfate polyacrylamide gel electrophoresis.
siRNA: small interfering RNA
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THAP: Thanatos‐associated protein.
TNF‐α: Tumor necrosis factor alpha.
TNF‐R: TNF receptor.
TRAIL: Tumor necrosis factor‐related apoptosis‐inducing ligand
WT1: Wilms’ tumor 1.

103

References

Algeciras‐Schimnich, A., Shen, L., Barnhart, B. C., Murmann, A. E., Burkhardt, J. K., and
Peter, M. E. (2002). Molecular ordering of the initial signaling events of CD95. Mol Cell
Biol 22, 207‐220.
Almasan, A., and Ashkenazi, A. (2003). Apo2L/TRAIL: apoptosis signaling, biology, and
potential for cancer therapy. Cytokine Growth Factor Rev 14, 337‐348.
Ashkenazi, A., and Dixit, V. M. (1998). Death receptors: signaling and modulation.
Science 281, 1305‐1308.
Ashkenazi, A., and Herbst, R. S. (2008). To kill a tumor cell: the potential of proapoptotic
receptor agonists. J Clin Invest 118, 1979‐1990.
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C.,
Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999). Safety and antitumor activity of
recombinant soluble Apo2 ligand. J Clin Invest 104, 155‐162.
Bailly‐Maitre, B., de Sousa, G., Zucchini, N., Gugenheim, J., Boulukos, K. E., and Rahmani,
R. (2002). Spontaneous apoptosis in primary cultures of human and rat hepatocytes:
molecular mechanisms and regulation by dexamethasone. Cell Death Differ 9, 945‐955.
Baldwin, A. S., Jr. (1996). The NF‐kappa B and I kappa B proteins: new discoveries and
insights. Annu Rev Immunol 14, 649‐683.
Barkett, M., and Gilmore, T. D. (1999). Control of apoptosis by Rel/NF‐kappaB
transcription factors. Oncogene 18, 6910‐6924.
Barradas, M., Monjas, A., Diaz‐Meco, M. T., Serrano, M., and Moscat, J. (1999). The
downregulation of the pro‐apoptotic protein Par‐4 is critical for Ras‐induced survival
and tumor progression. EMBO J 18, 6362‐6369.
Bieberich, E., MacKinnon, S., Silva, J., Noggle, S., and Condie, B. G. (2003). Regulation of
cell death in mitotic neural progenitor cells by asymmetric distribution of prostate
apoptosis response 4 (PAR‐4) and simultaneous elevation of endogenous ceramide. J
Cell Biol 162, 469‐479.
Bieberich, E., Silva, J., Wang, G., Krishnamurthy, K., and Condie, B. G. (2004). Selective
apoptosis of pluripotent mouse and human stem cells by novel ceramide analogues

104

prevents teratoma formation and enriches for neural precursors in ES cell‐derived
neural transplants. J Cell Biol 167, 723‐734.
Boatright, K. M., Renatus, M., Scott, F. L., Sperandio, S., Shin, H., Pedersen, I. M., Ricci, J.
E., Edris, W. A., Sutherlin, D. P., Green, D. R., and Salvesen, G. S. (2003). A unified model
for apical caspase activation. Mol Cell 11, 529‐541.
Boehrer, S., Chow, K. U., Puccetti, E., Ruthardt, M., Godzisard, S., Krapohl, A., Schneider,
B., Hoelzer, D., Mitrou, P. S., Rangnekar, V. M., and Weidmann, E. (2001). Deregulated
expression of prostate apoptosis response gene‐4 in less differentiated lymphocytes and
inverse expressional patterns of par‐4 and bcl‐2 in acute lymphocytic leukemia. Hematol
J 2, 103‐107.
Boghaert, E. R., Sells, S. F., Walid, A. J., Malone, P., Williams, N. M., Weinstein, M. H.,
Strange, R., and Rangnekar, V. M. (1997). Immunohistochemical analysis of the
proapoptotic protein Par‐4 in normal rat tissues. Cell Growth Differ 8, 881‐890.
Breckenridge, D. G., Nguyen, M., Kuppig, S., Reth, M., and Shore, G. C. (2002). The
procaspase‐8 isoform, procaspase‐8L, recruited to the BAP31 complex at the
endoplasmic reticulum. Proc Natl Acad Sci U S A 99, 4331‐4336.
Chakraborty, M., Qiu, S. G., Vasudevan, K. M., and Rangnekar, V. M. (2001). Par‐4 drives
trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and
tumor regression. Cancer Res 61, 7255‐7263.
Chang, D. W., Xing, Z., Pan, Y., Algeciras‐Schimnich, A., Barnhart, B. C., Yaish‐Ohad, S.,
Peter, M. E., and Yang, X. (2002a). c‐FLIP(L) is a dual function regulator for caspase‐8
activation and CD95‐mediated apoptosis. EMBO J 21, 3704‐3714.
Chang, S., Kim, J. H., and Shin, J. (2002b). p62 forms a ternary complex with PKCzeta and
PAR‐4 and antagonizes PAR‐4‐induced PKCzeta inhibition. FEBS Lett 510, 57‐61.
Cheema, S. K., Mishra, S. K., Rangnekar, V. M., Tari, A. M., Kumar, R., and Lopez‐
Berestein, G. (2003). Par‐4 transcriptionally regulates Bcl‐2 through a WT1‐binding site
on the bcl‐2 promoter. J Biol Chem 278, 19995‐20005.
Chen, X., Thakkar, H., Tyan, F., Gim, S., Robinson, H., Lee, C., Pandey, S. K., Nwokorie, C.,
Onwudiwe, N., and Srivastava, R. K. (2001). Constitutively active Akt is an important
regulator of TRAIL sensitivity in prostate cancer. Oncogene 20, 6073‐6083.

105

Chou, A. H., Tsai, H. F., Lin, L. L., Hsieh, S. L., Hsu, P. I., and Hsu, P. N. (2001). Enhanced
proliferation and increased IFN‐gamma production in T cells by signal transduced
through TNF‐related apoptosis‐inducing ligand. J Immunol 167, 1347‐1352.
Cornelis, S., Bruynooghe, Y., Van Loo, G., Saelens, X., Vandenabeele, P., and Beyaert, R.
(2005). Apoptosis of hematopoietic cells induced by growth factor withdrawal is
associated with caspase‐9 mediated cleavage of Raf‐1. Oncogene 24, 1552‐1562.
Cowling, V., and Downward, J. (2002). Caspase‐6 is the direct activator of caspase‐8 in
the cytochrome c‐induced apoptosis pathway: absolute requirement for removal of
caspase‐6 prodomain. Cell Death Differ 9, 1046‐1056.
Cross, F. R., Garber, E. A., Pellman, D., and Hanafusa, H. (1984). A short sequence in the
p60src N terminus is required for p60src myristylation and membrane association and
for cell transformation. Mol Cell Biol 4, 1834‐1842.
Danial, N. N., and Korsmeyer, S. J. (2004). Cell death: critical control points. Cell 116,
205‐219.
Davies, M. A., Koul, D., Dhesi, H., Berman, R., McDonnell, T. J., McConkey, D., Yung, W.
K., and Steck, P. A. (1999). Regulation of Akt/PKB activity, cellular growth, and apoptosis
in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59, 2551‐2556.
Diaz‐Meco, M. T., Lallena, M. J., Monjas, A., Frutos, S., and Moscat, J. (1999).
Inactivation of the inhibitory kappaB protein kinase/nuclear factor kappaB pathway by
Par‐4 expression potentiates tumor necrosis factor alpha‐induced apoptosis. J Biol Chem
274, 19606‐19612.
Diaz‐Meco, M. T., Municio, M. M., Frutos, S., Sanchez, P., Lozano, J., Sanz, L., and
Moscat, J. (1996). The product of par‐4, a gene induced during apoptosis, interacts
selectively with the atypical isoforms of protein kinase C. Cell 86, 777‐786.
Djerbi, M., Screpanti, V., Catrina, A. I., Bogen, B., Biberfeld, P., and Grandien, A. (1999).
The inhibitor of death receptor signaling, FLICE‐inhibitory protein defines a new class of
tumor progression factors. J Exp Med 190, 1025‐1032.
Downward, J. (1998). Ras signalling and apoptosis. Curr Opin Genet Dev 8, 49‐54.
Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H. (1999). Mammalian caspases:
structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68,
383‐424.

106

El‐Guendy, N., and Rangnekar, V. M. (2003). Apoptosis by Par‐4 in cancer and
neurodegenerative diseases. Exp Cell Res 283, 51‐66.
El‐Guendy, N., Zhao, Y., Gurumurthy, S., Burikhanov, R., and Rangnekar, V. M. (2003).
Identification of a unique core domain of par‐4 sufficient for selective apoptosis
induction in cancer cells. Mol Cell Biol 23, 5516‐5525.
El‐Guendy, N. M. (2002). Structure and function analysis of Par‐4. In, (Lexington, Ky.:
[University of Kentucky Libraries]).
Englert, C., Hou, X., Maheswaran, S., Bennett, P., Ngwu, C., Re, G. G., Garvin, A. J.,
Rosner, M. R., and Haber, D. A. (1995). WT1 suppresses synthesis of the epidermal
growth factor receptor and induces apoptosis. EMBO J 14, 4662‐4675.
Feig, C., Tchikov, V., Schutze, S., and Peter, M. E. (2007). Palmitoylation of CD95
facilitates formation of SDS‐stable receptor aggregates that initiate apoptosis signaling.
EMBO J 26, 221‐231.
Fisher, T. C., Milner, A. E., Gregory, C. D., Jackman, A. L., Aherne, G. W., Hartley, J. A.,
Dive, C., and Hickman, J. A. (1993). bcl‐2 modulation of apoptosis induced by anticancer
drugs: resistance to thymidylate stress is independent of classical resistance pathways.
Cancer Res 53, 3321‐3326.
Gao, S., Wang, H., Lee, P., Melamed, J., Li, C. X., Zhang, F., Wu, H., Zhou, L., and Wang, Z.
(2006). Androgen receptor and prostate apoptosis response factor‐4 target the c‐FLIP
gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol 36,
463‐483.
Garcia‐Cao, I., Duran, A., Collado, M., Carrascosa, M. J., Martin‐Caballero, J., Flores, J.
M., Diaz‐Meco, M. T., Moscat, J., and Serrano, M. (2005). Tumour‐suppression activity of
the proapoptotic regulator Par4. EMBO Rep 6, 577‐583.
Goswami, A., Burikhanov, R., de Thonel, A., Fujita, N., Goswami, M., Zhao, Y., Eriksson, J.
E., Tsuruo, T., and Rangnekar, V. M. (2005). Binding and phosphorylation of par‐4 by akt
is essential for cancer cell survival. Mol Cell 20, 33‐44.
Goswami, A., Qiu, S., Dexheimer, T. S., Ranganathan, P., Burikhanov, R., Pommier, Y.,
and Rangnekar, V. M. (2008). Par‐4 binds to topoisomerase 1 and attenuates its DNA
relaxation activity. Cancer Res 68, 6190‐6198.

107

Gottesman, M. M., and Pastan, I. (1993). Biochemistry of multidrug resistance mediated
by the multidrug transporter. Annu Rev Biochem 62, 385‐427.
Gurumurthy, S., Goswami, A., Vasudevan, K. M., and Rangnekar, V. M. (2005).
Phosphorylation of Par‐4 by protein kinase A is critical for apoptosis. Mol Cell Biol 25,
1146‐1161.
Gurumurthy, S., and Rangnekar, V. M. (2004). Par‐4 inducible apoptosis in prostate
cancer cells. J Cell Biochem 91, 504‐512.
Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57‐70.
Harada, K., Toyooka, S., Shivapurkar, N., Maitra, A., Reddy, J. L., Matta, H., Miyajima, K.,
Timmons, C. F., Tomlinson, G. E., Mastrangelo, D., et al. (2002). Deregulation of caspase
8 and 10 expression in pediatric tumors and cell lines. Cancer Res 62, 5897‐5901.
Harrington, E. A., Bennett, M. R., Fanidi, A., and Evan, G. I. (1994). c‐Myc‐induced
apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13, 3286‐3295.
Helfer, B., Boswell, B. C., Finlay, D., Cipres, A., Vuori, K., Bong Kang, T., Wallach, D.,
Dorfleutner, A., Lahti, J. M., Flynn, D. C., and Frisch, S. M. (2006). Caspase‐8 promotes
cell motility and calpain activity under nonapoptotic conditions. Cancer Res 66, 4273‐
4278.
Inoue, N., Manabe, N., Matsui, T., Maeda, A., Nakagawa, S., Wada, S., and Miyamoto, H.
(2003). Roles of tumor necrosis factor‐related apoptosis‐inducing ligand signaling
pathway in granulosa cell apoptosis during atresia in pig ovaries. J Reprod Dev 49, 313‐
321.
Jahani‐Asl, A., Basak, A., and Tsang, B. K. (2007). Caspase‐3‐mediated cleavage of Akt:
involvement of non‐consensus sites and influence of phosphorylation. FEBS Lett 581,
2883‐2888.
Johnstone, R. W., See, R. H., Sells, S. F., Wang, J., Muthukkumar, S., Englert, C., Haber, D.
A., Licht, J. D., Sugrue, S. P., Roberts, T., et al. (1996). A novel repressor, par‐4,
modulates transcription and growth suppression functions of the Wilms' tumor
suppressor WT1. Mol Cell Biol 16, 6945‐6956.
Jones, R. G., Elford, A. R., Parsons, M. J., Wu, L., Krawczyk, C. M., Yeh, W. C., Hakem, R.,
Rottapel, R., Woodgett, J. R., and Ohashi, P. S. (2002). CD28‐dependent activation of

108

protein kinase B/Akt blocks Fas‐mediated apoptosis by preventing death‐inducing
signaling complex assembly. J Exp Med 196, 335‐348.
Joshi, J., Fernandez‐Marcos, P. J., Galvez, A., Amanchy, R., Linares, J. F., Duran, A.,
Pathrose, P., Leitges, M., Canamero, M., Collado, M., et al. (2008). Par‐4 inhibits Akt and
suppresses Ras‐induced lung tumorigenesis. EMBO J 27, 2181‐2193.
Kang, T. B., Ben‐Moshe, T., Varfolomeev, E. E., Pewzner‐Jung, Y., Yogev, N., Jurewicz, A.,
Waisman, A., Brenner, O., Haffner, R., Gustafsson, E., et al. (2004). Caspase‐8 serves
both apoptotic and nonapoptotic roles. J Immunol 173, 2976‐2984.
Kerr, J. F., Winterford, C. M., and Harmon, B. V. (1994). Apoptosis. Its significance in
cancer and cancer therapy. Cancer 73, 2013‐2026.
Kidd, V. J. (1998). Proteolytic activities that mediate apoptosis. Annu Rev Physiol 60,
533‐573.
Kim, H. S., Lee, J. W., Soung, Y. H., Park, W. S., Kim, S. Y., Lee, J. H., Park, J. Y., Cho, Y. G.,
Kim, C. J., Jeong, S. W., et al. (2003). Inactivating mutations of caspase‐8 gene in
colorectal carcinomas. Gastroenterology 125, 708‐715.
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., and Ashkenazi, A.
(2000). Apo2L/TRAIL‐dependent recruitment of endogenous FADD and caspase‐8 to
death receptors 4 and 5. Immunity 12, 611‐620.
Koseki, T., Inohara, N., Chen, S., and Nunez, G. (1998). ARC, an inhibitor of apoptosis
expressed in skeletal muscle and heart that interacts selectively with caspases. Proc Natl
Acad Sci U S A 95, 5156‐5160.
Kukoc‐Zivojnov, N., Puccetti, E., Chow, K. U., Bergmann, M., Ruthardt, M., Hoelzer, D.,
Mitrou, P. S., Weidmann, E., and Boehrer, S. (2004). Prostate apoptosis response gene‐4
(par‐4) abrogates the survival function of p185(BCR‐ABL) in hematopoietic cells. Exp
Hematol 32, 649‐656.
Lafuente, M. J., Martin, P., Garcia‐Cao, I., Diaz‐Meco, M. T., Serrano, M., and Moscat, J.
(2003). Regulation of mature T lymphocyte proliferation and differentiation by Par‐4.
EMBO J 22, 4689‐4698.
Lee, J. C., Schickling, O., Stegh, A. H., Oshima, R. G., Dinsdale, D., Cohen, G. M., and
Peter, M. E. (2002). DEDD regulates degradation of intermediate filaments during
apoptosis. J Cell Biol 158, 1051‐1066.

109

Lemaire, C., Godefroy, N., Costina‐Parvu, I., Rincheval, V., Renaud, F., Trotot, P.,
Bouleau, S., Mignotte, B., and Vayssiere, J. L. (2005). Caspase‐9 can antagonize p53‐
induced apoptosis by generating a p76(Rb) truncated form of Rb. Oncogene 24, 3297‐
3308.
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and
Wang, X. (1997). Cytochrome c and dATP‐dependent formation of Apaf‐1/caspase‐9
complex initiates an apoptotic protease cascade. Cell 91, 479‐489.
Longley, D. B., Wilson, T. R., McEwan, M., Allen, W. L., McDermott, U., Galligan, L., and
Johnston, P. G. (2006). c‐FLIP inhibits chemotherapy‐induced colorectal cancer cell
death. Oncogene 25, 838‐848.
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E.,
Housman, D. E., and Jacks, T. (1994). p53 status and the efficacy of cancer therapy in
vivo. Science 266, 807‐810.
Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. (1993). p53‐dependent apoptosis
modulates the cytotoxicity of anticancer agents. Cell 74, 957‐967.
Lucas, T., Pratscher, B., Krishnan, S., Fink, D., Gunsberg, P., Wolschek, M., Wacheck, V.,
Muster, T., Romirer, I., Wolff, K., et al. (2001). Differential expression levels of Par‐4 in
melanoma. Melanoma Res 11, 379‐383.
Magnuson, B. A., Raju, R. V., Moyana, T. N., and Sharma, R. K. (1995). Increased N‐
myristoyltransferase activity observed in rat and human colonic tumors. J Natl Cancer
Inst 87, 1630‐1635.
Mattson, M. P., Duan, W., Chan, S. L., and Camandola, S. (1999). Par‐4: an emerging
pivotal player in neuronal apoptosis and neurodegenerative disorders. J Mol Neurosci
13, 17‐30.
Minn, A. J., Rudin, C. M., Boise, L. H., and Thompson, C. B. (1995). Expression of bcl‐xL
can confer a multidrug resistance phenotype. Blood 86, 1903‐1910.
Miyashita, T., and Reed, J. C. (1992). bcl‐2 gene transfer increases relative resistance of
S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by
glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52, 5407‐5411.
Morgenbesser, S. D., Williams, B. O., Jacks, T., and DePinho, R. A. (1994). p53‐dependent
apoptosis produced by Rb‐deficiency in the developing mouse lens. Nature 371, 72‐74.

110

Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1996). Apoptosis and APC in colorectal
tumorigenesis. Proc Natl Acad Sci U S A 93, 7950‐7954.
Nakanishi, K., Maruyama, M., Shibata, T., and Morishima, N. (2001). Identification of a
caspase‐9 substrate and detection of its cleavage in programmed cell death during
mouse development. J Biol Chem 276, 41237‐41244.
Nalca, A., Qiu, S. G., El‐Guendy, N., Krishnan, S., and Rangnekar, V. M. (1999). Oncogenic
Ras sensitizes cells to apoptosis by Par‐4. J Biol Chem 274, 29976‐29983.
Ng, F. W., Nguyen, M., Kwan, T., Branton, P. E., Nicholson, D. W., Cromlish, J. A., and
Shore, G. C. (1997). p28 Bap31, a Bcl‐2/Bcl‐XL‐ and procaspase‐8‐associated protein in
the endoplasmic reticulum. J Cell Biol 139, 327‐338.
Nomura, M., Shimizu, S., Sugiyama, T., Narita, M., Ito, T., Matsuda, H., and Tsujimoto, Y.
(2003). 14‐3‐3 Interacts directly with and negatively regulates pro‐apoptotic Bax. J Biol
Chem 278, 2058‐2065.
Ozoren, N., and El‐Deiry, W. S. (2002). Defining characteristics of Types I and II apoptotic
cells in response to TRAIL. Neoplasia 4, 551‐557.
Ozoren, N., Kim, K., Burns, T. F., Dicker, D. T., Moscioni, A. D., and El‐Deiry, W. S. (2000).
The caspase 9 inhibitor Z‐LEHD‐FMK protects human liver cells while permitting death of
cancer cells exposed to tumor necrosis factor‐related apoptosis‐inducing ligand. Cancer
Res 60, 6259‐6265.
Page, G., Kogel, D., Rangnekar, V., and Scheidtmann, K. H. (1999). Interaction partners of
Dlk/ZIP kinase: co‐expression of Dlk/ZIP kinase and Par‐4 results in cytoplasmic
retention and apoptosis. Oncogene 18, 7265‐7273.
Pennati, M., Binda, M., De Cesare, M., Pratesi, G., Folini, M., Citti, L., Daidone, M. G.,
Zunino, F., and Zaffaroni, N. (2004). Ribozyme‐mediated down‐regulation of survivin
expression sensitizes human melanoma cells to topotecan in vitro and in vivo.
Carcinogenesis 25, 1129‐1136.
Peter, M. E. (2000). The TRAIL DISCussion: It is FADD and caspase‐8! Cell Death Differ 7,
759‐760.
Philchenkov, A., Zavelevich, M., Kroczak, T. J., and Los, M. (2004). Caspases and cancer:
mechanisms of inactivation and new treatment modalities. Exp Oncol 26, 82‐97.

111

Phillips, A. C., Bates, S., Ryan, K. M., Helin, K., and Vousden, K. H. (1997). Induction of
DNA synthesis and apoptosis are separable functions of E2F‐1. Genes Dev 11, 1853‐
1863.
Plati, J., Bucur, O., and Khosravi‐Far, R. (2008). Dysregulation of apoptotic signaling in
cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem 104, 1124‐
1149.
Qin, Z. H., Wang, Y., Kikly, K. K., Sapp, E., Kegel, K. B., Aronin, N., and DiFiglia, M. (2001).
Pro‐caspase‐8 is predominantly localized in mitochondria and released into cytoplasm
upon apoptotic stimulation. J Biol Chem 276, 8079‐8086.
Qiu, G., Ahmed, M., Sells, S. F., Mohiuddin, M., Weinstein, M. H., and Rangnekar, V. M.
(1999a). Mutually exclusive expression patterns of Bcl‐2 and Par‐4 in human prostate
tumors consistent with down‐regulation of Bcl‐2 by Par‐4. Oncogene 18, 623‐631.
Qiu, S. G., Krishnan, S., el‐Guendy, N., and Rangnekar, V. M. (1999b). Negative
regulation of Par‐4 by oncogenic Ras is essential for cellular transformation. Oncogene
18, 7115‐7123.
Rajala, R. V., Radhi, J. M., Kakkar, R., Datla, R. S., and Sharma, R. K. (2000). Increased
expression of N‐myristoyltransferase in gallbladder carcinomas. Cancer 88, 1992‐1999.
Ranganathan, P., and Rangnekar, V. M. (2005). Regulation of cancer cell survival by Par‐
4. Ann N Y Acad Sci 1059, 76‐85.
Rao, L., Debbas, M., Sabbatini, P., Hockenbery, D., Korsmeyer, S., and White, E. (1992).
The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19‐kDa and
Bcl‐2 proteins. Proc Natl Acad Sci U S A 89, 7742‐7746.
Rao, V. N., Shao, N., Ahmad, M., and Reddy, E. S. (1996). Antisense RNA to the putative
tumor suppressor gene BRCA1 transforms mouse fibroblasts. Oncogene 12, 523‐528.
Ravi, R., and Bedi, A. (2002). Sensitization of tumor cells to Apo2 ligand/TRAIL‐induced
apoptosis by inhibition of casein kinase II. Cancer Res 62, 4180‐4185.
Reed, J. C. (1995). Regulation of apoptosis by bcl‐2 family proteins and its role in cancer
and chemoresistance. Curr Opin Oncol 7, 541‐546.
Reed, J. C. (1999). Dysregulation of apoptosis in cancer. J Clin Oncol 17, 2941‐2953.

112

Roussigne, M., Cayrol, C., Clouaire, T., Amalric, F., and Girard, J. P. (2003). THAP1 is a
nuclear proapoptotic factor that links prostate‐apoptosis‐response‐4 (Par‐4) to PML
nuclear bodies. Oncogene 22, 2432‐2442.
Sahara, S., Aoto, M., Eguchi, Y., Imamoto, N., Yoneda, Y., and Tsujimoto, Y. (1999).
Acinus is a caspase‐3‐activated protein required for apoptotic chromatin condensation.
Nature 401, 168‐173.
Salmena, L., Lemmers, B., Hakem, A., Matysiak‐Zablocki, E., Murakami, K., Au, P. Y.,
Berry, D. M., Tamblyn, L., Shehabeldin, A., Migon, E., et al. (2003). Essential role for
caspase 8 in T‐cell homeostasis and T‐cell‐mediated immunity. Genes Dev 17, 883‐895.
Sanz‐Navares, E., Fernandez, N., Kazanietz, M. G., and Rotenberg, S. A. (2001). Atypical
protein kinase Czeta suppresses migration of mouse melanoma cells. Cell Growth Differ
12, 517‐524.
Sells, S. F., Han, S. S., Muthukkumar, S., Maddiwar, N., Johnstone, R., Boghaert, E., Gillis,
D., Liu, G., Nair, P., Monnig, S., et al. (1997). Expression and function of the leucine
zipper protein Par‐4 in apoptosis. Mol Cell Biol 17, 3823‐3832.
Sells, S. F., Wood, D. P., Jr., Joshi‐Barve, S. S., Muthukumar, S., Jacob, R. J., Crist, S. A.,
Humphreys, S., and Rangnekar, V. M. (1994). Commonality of the gene programs
induced by effectors of apoptosis in androgen‐dependent and ‐independent prostate
cells. Cell Growth Differ 5, 457‐466.
Selvakumar, P., Lakshmikuttyamma, A., Shrivastav, A., Das, S. B., Dimmock, J. R., and
Sharma, R. K. (2007). Potential role of N‐myristoyltransferase in cancer. Prog Lipid Res
46, 1‐36.
Shin, S., Lee, Y., Kim, W., Ko, H., Choi, H., and Kim, K. (2005). Caspase‐2 primes cancer
cells for TRAIL‐mediated apoptosis by processing procaspase‐8. EMBO J 24, 3532‐3542.
Shivapurkar, N., Reddy, J., Matta, H., Sathyanarayana, U. G., Huang, C. X., Toyooka, S.,
Minna, J. D., Chaudhary, P. M., and Gazdar, A. F. (2002). Loss of expression of death‐
inducing signaling complex (DISC) components in lung cancer cell lines and the influence
of MYC amplification. Oncogene 21, 8510‐8514.
Song, J. H., Tse, M. C., Bellail, A., Phuphanich, S., Khuri, F., Kneteman, N. M., and Hao, C.
(2007). Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis‐
inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung
carcinoma cells. Cancer Res 67, 6946‐6955.

113

Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H.,
and Walczak, H. (2000). FADD/MORT1 and caspase‐8 are recruited to TRAIL receptors 1
and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12, 599‐
609.
Stegh, A. H., Herrmann, H., Lampel, S., Weisenberger, D., Andra, K., Seper, M., Wiche,
G., Krammer, P. H., and Peter, M. E. (2000). Identification of the cytolinker plectin as a
major early in vivo substrate for caspase 8 during CD95‐ and tumor necrosis factor
receptor‐mediated apoptosis. Mol Cell Biol 20, 5665‐5679.
Strasser, A., O'Connor, L., and Dixit, V. M. (2000). Apoptosis signaling. Annu Rev
Biochem 69, 217‐245.
Stupack, D. G., Teitz, T., Potter, M. D., Mikolon, D., Houghton, P. J., Kidd, V. J., Lahti, J.
M., and Cheresh, D. A. (2006). Potentiation of neuroblastoma metastasis by loss of
caspase‐8. Nature 439, 95‐99.
Teitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G.,
Look, A. T., Lahti, J. M., and Kidd, V. J. (2000). Caspase 8 is deleted or silenced
preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6,
529‐535.
Todaro, M., Lombardo, Y., Francipane, M. G., Alea, M. P., Cammareri, P., Iovino, F., Di
Stefano, A. B., Di Bernardo, C., Agrusa, A., Condorelli, G., et al. (2008). Apoptosis
resistance in epithelial tumors is mediated by tumor‐cell‐derived interleukin‐4. Cell
Death Differ 15, 762‐772.
Tommasino, M., and Crawford, L. (1995). Human papillomavirus E6 and E7: proteins
which deregulate the cell cycle. Bioessays 17, 509‐518.
Tortora, G., and Ciardiello, F. (2002). Protein kinase A as target for novel integrated
strategies of cancer therapy. Ann N Y Acad Sci 968, 139‐147.
Uchida, H., Shinoura, N., Kitayama, J., Watanabe, T., Nagawa, H., and Hamada, H.
(2003). 5‐Fluorouracil efficiently enhanced apoptosis induced by adenovirus‐mediated
transfer of caspase‐8 in DLD‐1 colon cancer cells. J Gene Med 5, 287‐299.
Van de Craen, M., Declercq, W., Van den brande, I., Fiers, W., and Vandenabeele, P.
(1999). The proteolytic procaspase activation network: an in vitro analysis. Cell Death
Differ 6, 1117‐1124.

114

Varadhachary, A. S., Edidin, M., Hanlon, A. M., Peter, M. E., Krammer, P. H., and
Salgame, P. (2001). Phosphatidylinositol 3'‐kinase blocks CD95 aggregation and caspase‐
8 cleavage at the death‐inducing signaling complex by modulating lateral diffusion of
CD95. J Immunol 166, 6564‐6569.
Varadhachary, A. S., Peter, M. E., Perdow, S. N., Krammer, P. H., and Salgame, P. (1999).
Selective up‐regulation of phosphatidylinositol 3'‐kinase activity in Th2 cells inhibits
caspase‐8 cleavage at the death‐inducing complex: a mechanism for Th2 resistance from
Fas‐mediated apoptosis. J Immunol 163, 4772‐4779.
Varfolomeev, E. E., Schuchmann, M., Luria, V., Chiannilkulchai, N., Beckmann, J. S., Mett,
I. L., Rebrikov, D., Brodianski, V. M., Kemper, O. C., Kollet, O., et al. (1998). Targeted
disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF
receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9, 267‐276.
Vasudevan, K. M., Ranganathan, P., and Rangnekar, V. M. (2006). Regulation of Par‐4 by
oncogenic Ras. Methods Enzymol 407, 422‐442.
Vetterkind, S., Illenberger, S., Kubicek, J., Boosen, M., Appel, S., Naim, H. Y.,
Scheidtmann, K. H., and Preuss, U. (2005). Binding of Par‐4 to the actin cytoskeleton is
essential for Par‐4/Dlk‐mediated apoptosis. Exp Cell Res 305, 392‐408.
Vetterkind, S., and Morgan, K. G. (2008). The Pro‐Apoptotic Protein Par‐4 Facilitates
Vascular Contractility by Cytoskeletal Targeting of Zipk. J Cell Mol Med.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones,
J., Woodward, A., Le, T., et al. (1999). Tumoricidal activity of tumor necrosis factor‐
related apoptosis‐inducing ligand in vivo. Nat Med 5, 157‐163.
Wang, G., Ahmad, K. A., and Ahmed, K. (2006). Role of protein kinase CK2 in the
regulation of tumor necrosis factor‐related apoptosis inducing ligand‐induced apoptosis
in prostate cancer cells. Cancer Res 66, 2242‐2249.
Wu, X. X., Ogawa, O., and Kakehi, Y. (2004). TRAIL and chemotherapeutic drugs in cancer
therapy. Vitam Horm 67, 365‐383.
Xie, J., and Guo, Q. (2004). Par‐4 inhibits choline uptake by interacting with CHT1 and
reducing its incorporation on the plasma membrane. J Biol Chem 279, 28266‐28275.
Xie, J., and Guo, Q. (2005). PAR‐4 is involved in regulation of beta‐secretase cleavage of
the Alzheimer amyloid precursor protein. J Biol Chem 280, 13824‐13832.

115

Yu, J., Ni, M., Xu, J., Zhang, H., Gao, B., Gu, J., Chen, J., Zhang, L., Wu, M., Zhen, S., and
Zhu, J. (2002). Methylation profiling of twenty promoter‐CpG islands of genes which
may contribute to hepatocellular carcinogenesis. BMC Cancer 2, 29.
Zakeri, Z. F., Quaglino, D., Latham, T., and Lockshin, R. A. (1993). Delayed
internucleosomal DNA fragmentation in programmed cell death. FASEB J 7, 470‐478.
Zhang, H., Xu, Q., Krajewski, S., Krajewska, M., Xie, Z., Fuess, S., Kitada, S., Pawlowski, K.,
Godzik, A., and Reed, J. C. (2000). BAR: An apoptosis regulator at the intersection of
caspases and Bcl‐2 family proteins. Proc Natl Acad Sci U S A 97, 2597‐2602.
Zhang, X., Jin, T. G., Yang, H., DeWolf, W. C., Khosravi‐Far, R., and Olumi, A. F. (2004).
Persistent c‐FLIP(L) expression is necessary and sufficient to maintain resistance to
tumor necrosis factor‐related apoptosis‐inducing ligand‐mediated apoptosis in prostate
cancer. Cancer Res 64, 7086‐7091.
Zhao, Y., Burikhanov, R., Qiu, S., Lele, S. M., Jennings, C. D., Bondada, S., Spear, B., and
Rangnekar, V. M. (2007). Cancer resistance in transgenic mice expressing the SAC
module of Par‐4. Cancer Res 67, 9276‐9285.

116

VITA

NAME: Padhma Ranganathan
DATE AND PLACE OF BIRTH: November 17, 1977. Chennai, India
EDUCATION
M.Sc. Microbiology 1998-2001
University of Madras, Chennai. India
B.Sc. Nutrition and Dietetics 1995-98
University of Madras, Chennai, India
AWARDS
University of Kentucky, Graduate School Fellowship (2002-03)
PUBLICATIONS
1. Padhma Ranganathan, Ravshan Burikhanov, Steve Schwarze and Vivek M Rangnekar.
Par-4 – A critical determinant of TRAIL sensitivity in normal and cancer cells (To be
submitted)
2. Padhma Ranganathan, Ravshan Burikhanov and Vivek M Rangnekar. Co-operation of
caspases -8 and -9 for the activation of Par-4 during apoptosis (Manuscript in preparation)
3. Anindya Goswami, Shirley Qiu, Thomas S. Dexheimer, Padhma Ranganathan, Ravshan
Burikhanov, Yves Pommier and Vivek M. Rangnekar (2008) Par-4 Binds to
Topoisomerase 1 and Attenuates Its DNA Relaxation Activity. Cancer Res. 68(15):6190‐
6198
4. Anindya Goswami, Padhma Ranganathan and Vivek M. Rangnekar (2006). The
Phosphoinositide 3-Kinase/Akt1/Par-4 Axis: A Cancer-Selective Therapeutic Target.
Cancer Res. 66: 2889-2892.
5. Krishna Murthi Vasudevan, Padhma Ranganathan and Vivek M. Rangnekar (2006).
Regulation of Par-4 by Oncogenic Ras. Methods Enzymol. 407: 422-442
6. Padhma Ranganathan and Vivek M. Rangnekar (2005). Exploiting the TSA Connections
to Overcome Apoptosis-Resistance. Cancer Biol & Ther. 4 (4): 882-390
7. Padhma Ranganathan and Vivek M. Rangnekar (2005). Regulation of Cancer Cell
Survival by Par-4. Ann. N.Y. Acad. Sci. 1059: 76–85.

117

MEETINGS AND CONFERENCES
1. Cold spring harbor, cell death meeting (2007) Critical requirement of Par-4 in TRAIL
induced apoptosis of cancer cells - Padhma Ranganathan, Ravshan Burikhanov, Anindya
Goswami and Vivek Rangnekar.
2. AACR (2008) Critical role of Par-4 in determining sensitivity of cancer cells to TRAIL Padhma Ranganathan, Ravshan Burikhanov, and Vivek Rangnekar.

118

